Sandbox g15: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
mNo edit summary
 
(58 intermediate revisions by the same user not shown)
Line 4: Line 4:
! Antimicrobial Spectrum
! Antimicrobial Spectrum
! Dosing Information
! Dosing Information
! Common Adverse Reaction
! Notable Adverse Reaction
|-
|-
| '''Amikacin'''
| '''Amikacin'''
Line 37: Line 37:
* Rash
* Rash
* Diarrhea
* Diarrhea
* Abdominal cramping
* Cramping
|-
|-
| '''Amoxicillin-Clavulanate'''
| '''Amoxicillin-Clavulanate'''
Line 65: Line 65:
|
|
* Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (≤ 2,000 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
* Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (≤ 2,000 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
* Neonates (postnatal age > 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (< 1,200 g); 75 mg/ kg/24 hr divided q 8 hr IV or IM (1,200 - 2,000 g); 100 mg/kg/24 hr divided q 6 hr IV or IM (> 2,000 g)
* Neonates (postnatal age > 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (< 1,200 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (1,200–2,000 g); 100 mg/kg/24 hr divided q 6 hr IV or IM (> 2,000 g)
* Children: 100-200 mg/kg/24 hr divided q 6 hr IV or IM
* Children: 100-200 mg/kg/24 hr divided q 6 hr IV or IM
* Adults: 250-500 mg q 4-8 hr IV or IM
* Adults: 250-500 mg q 4-8 hr IV or IM
Line 107: Line 107:
|
|
* Neonates (postnatal age ≤ 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (≤ 2,000 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
* Neonates (postnatal age ≤ 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (≤ 2,000 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
* Neonates (postnatal age > 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (< 1,200 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (1,200 - 2,000 g); 120 mg/kg/24 hr divided q 6-8 hr IV or IM (> 2,000 g)
* Neonates (postnatal age > 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (< 1,200 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (1,200–2,000 g); 120 mg/kg/24 hr divided q 6-8 hr IV or IM (> 2,000 g)
* Children: 90-120 mg/kg/24 hr divided q 6-8 hr IV or IM
* Children: 90-120 mg/kg/24 hr divided q 6-8 hr IV or IM
* Adults: 1-2 g IV or IM q 8-12 hr (max dose: 8 g/24 hr)
* Adults: 1-2 g IV or IM q 8-12 hr (max dose: 8 g/24 hr)
Line 142: Line 142:
* Rash
* Rash
* Eosinophilia
* Eosinophilia
* Serum sickness
* Serum sickness-like reaction
|-
|-
| '''Cefadroxil'''
| '''Cefadroxil'''
Line 222: Line 222:
|
|
* Hypoprothrombinemia
* Hypoprothrombinemia
* Disulfiram-life effect
* Disulfiram-life reaction
|-
|-
| '''Cefotaxime'''
| '''Cefotaxime'''
Line 237: Line 237:
* Eosinophilia
* Eosinophilia
|-
|-
| '''Cefotetan'''
|
|
'''Cefotetan  disodium'''
* S. aureus
 
* Streptococcus
Cefotan. Injection.
* H. influenzae
 
* E. coli
* Klebsiella
* Proteus
* Bacteroides
|
|
'''2nd generation cephalosporin active against ''S. aureus, Streptococcus, H. influenzae, E. coli, Klebsiella, Proteus, ''and ''Bacteroides.  ''Inactive  against  ''Enterobacter.'''''
* Children: 40-80 mg/kg/24 hr divided IV or IM q 12 hr
 
* Adults: 2-4 g/24 hr divided q 12 hr IV or IM (max dose: 6 g/24 hr)
Children: 40-80 mg/kg/24 hr divided IV or IM q 12 hr.
 
|
|
''Cautions: ''Highly protein-bound cephalosporin, poor CNS penetration; -Lactam safety profile (rash, eosinophilia), disulfiram-like reaction with alcohol. Renally eliminated (∼20% in bile).
* Rash
 
* Eosinophilia
* Hypoprothrombinemia
* Disulfiram-life reaction
|-
|-
| '''Cefoxitin'''
|
|
 
* S. aureus
 
* Streptococcus
* H. influenzae
* E. coli
* Klebsiella
* Proteus
* Bacteroides
|
|
Adults: 2-4 g/24 hr divided q 12 hr IV or IM (max dose: 6 g/24 hr).
* Neonates: 70-100 mg/kg/24 hr divided q 8-12 hr IV or IM
 
* Children: 80-160 mg/kg/24 hr divided q 6-8 hr IV or IM
* Adults: 1-2 g q 6-8 hr IV or IM (max dose: 12 g/24 hr)
|
|
 
* Rash
* Eosinophilia
|-
|-
| '''Cefpodoxime'''
|
|
'''Cefoxitin sodium '''Mefoxin. Injection.
* S. aureus
 
* Streptococcus
* H. influenzae
* M. catarrhalis
* N. gonorrhoeae
* E. coli
* Klebsiella
* Proteus
|
|
'''2nd generation cephalosporin active against ''S. aureus, Streptococcus, H. influenzae, E. coli, Klebsiella, Proteus, ''and ''Bacteroides.  ''Inactive  against  ''Enterobacter.'''''
* Children: 10 mg/kg/24 hr divided q 12 hr PO
 
* Adults: 200-800 mg/24 hr divided q 12 hr PO (max dose: 800 mg/24 hr)
|
|
''Cautions: ''Poor CNS penetration; -Lactam safety profile (rash, eosinophilia). Renally eliminated. Painful given intramuscularly.
* Rash
 
* Eosinophilia
|-
|-
| '''Cefprozil'''
|
|
 
* S. aureus
 
* Streptococcus
* H. influenzae
* E. coli
* M. catarrhalis
* Klebsiella
* Proteus
|
|
Neonates: 70-100 mg/kg/24 hr divided q 8-12 hr IV or IM.
* Children: 30 mg/kg/24 hr divided q 8-12 hr PO
 
* Adults: 500-1,000 mg/24 hr divided q 12 hr PO (max dose: 1.5 g/24 hr)
|
|
''Drug interaction: ''Probenecid.
* Rash
 
* Eosinophilia
|-
|-
| '''Ceftazidime'''
|
|
 
* Gram-positive pathogens
 
* Gram-negative pathogens including P. aeruginosa
|
|
Children: 80-160 mg/kg/24 hr divided q 6-8 hr IV or IM.
* Neonates (postnatal age ≤ 7 days): 100 mg/kg/24 hr divided q 12 hr IV or IM
 
* Neonates (postnatal age > 7 days): 100 mg/kg/24 hr divided q 12 hr IV or IM (< 1,200 g); 150 mg/kg/24 hr divided q 8 hr IV or IM (> 1,200 g)
* Children: 150 mg/kg/24 hr divided q 8 hr IV or IM
* Adults: 1-2 g q 8-12 hr IV or IM (max dose: 8-12 g/24 hr)
|
|
 
* Rash
 
* Eosinophilia
|-
|-
| '''Ceftiaoxime'''
|
|
 
* Gram-positive pathogens
 
* Gram-negative pathogens
|
|
Adults: 1-2 g q 6-8 hr IV or IM (max dose: 12 g/24 hr).
* Children: 150 mg/kg/24 hr divided q 6-8 hr IV or IM
 
* Adults: 1-2 g q 6-8 hr IV or IM (max dose: 12 g/24 hr)
|
|
 
* Rash
 
* Eosinophilia
|-
|-
| '''Ceftriaxone'''
|
|
'''Cefpodoxime  proxetil'''
* Gram-positive pathogens
 
* Gram-negative pathogens
Vantin.
 
Tablet: 100 mg, 200 mg.
 
Suspension: 50 mg/5 mL, 100 mg/5 mL.
 
|
|
'''3rd generation cephalosporin active against ''S. aureus, Streptococcus, H. influenzae, M. catarrhalis, N. gonorrhoeae,'''''
* Neonates: 50-75 mg/kg q 24 hr IV or IM
 
* Children: 50-75 mg/kg q 24 hr IV or IM
'''''E. coli, Klebsiella, ''and ''Proteus. ''No antipseudomonal activity.'''
* Adults: 1-2 g q 24 hr IV or IM (max dose: 4 g/24 hr)
 
Children: 10 mg/kg/24 hr divided q 12 hr PO.
 
Adults: 200-800 mg/24 hr divided q 12 hr PO (max dose: 800 mg/24 hr).
 
Uncomplicated gonorrhea: 200 mg PO as single-dose therapy.
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated. Does not adequately penetrate CNS. Increased bioavailability when taken with food.
* Rash
 
* Eosinophilia
''Drug interaction: ''Probenecid; antacids and H-2 receptor antagonists may decrease absorption.
 
|-
|-
| '''Cefuroxime'''
|
|
'''Cefprozil'''
* S. aureus
 
* Streptococcus
Cefzil.
* H. influenzae
 
* E. coli
Tablet: 250, 500 mg.
* M. catarrhalis
 
* Klebsiella
Suspension: 125 mg/5 mL, 250 mg/5 mL.
* Proteus
 
|
* Neonates: 40-100 mg/kg/24 hr divided q 12 hr IV or IM
* Children: 200-240 mg/kg/24 hr divided q 8 hr IV or IM; 20-30 mg/kg/24 hr divided q 8 hr PO
* Adults: 750-1,500 mg q 8 hr IV or IM (max dose: 6 g/24 hr)
|
|
'''2nd generation cephalosporin active against ''S. aureus, Streptococcus, H. influenzae, E. coli, M. catarrhalis, Klebsiella, ''and ''Proteus.'''''
* Rash
 
* Eosinophilia
Children: 30 mg/kg/24 hr divided q 8-12 hr PO.
 
Adults: 500-1,000 mg/24 hr divided q 12 hr PO (max dose: 1.5 g/24 hr).
 
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated. Good bioavailability; food does not affect bioavailability.
 
''Drug interaction: ''Probenecid.
 
|-
|-
| '''Cephalexin'''
|
|
'''Ceftazidime'''
* S. aureus
 
* Streptococcus
Fortaz, Ceptaz, Tazicer, Tazidime. Injection.
* E. coli
 
* Klebsiella
* Proteus
|
* Children: 25-100 mg/kg/24 hr divided q 6-8 hr PO
* Adults: 250-500 mg q 6 hr PO (max dose: 4 g/24 hr)
|
|
'''3rd generation cephalosporin active against gram-positive and gram-negative pathogens, including ''Pseudomonas aeruginosa.'''''
* Rash
 
* Eosinophilia
Neonates: Postnatal age ≤7 days: 100 mg/kg/24 hr divided q 12 hr IV or IM; 7 days ≤1,200 g: 100 mg/kg/24 hr divided q 12 hr IV or IM; 1,200 g: 150 mg/kg/24 hr divided q 8 hr IV or IM.
 
Children: 150 mg/kg/24 hr divided q 8 hr IV or IM (meningitis: 150 mg/kg/24 hr IV divided q 8 hr).
 
Adults: 1-2 g q 8-12 hr IV or IM (max dose: 8-12 g/24 hr).
 
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated. Increasing pathogen resistance developing with
 
long-term, widespread use.
 
''Drug interaction: ''Probenecid.
 
|-
|-
| '''Cephradine'''
|
|
'''Ceftiaoxime '''Cefizox. Injection.
* S. aureus
 
* Streptococcus
* E. coli
* Klebsiella
* Proteus
|
|
'''3rd generation cephalosporin active against gram-positive and gram-negative pathogens. No antipseudomonal activity.'''
* Children: 50-100 mg/kg/24 hr divided q 6-12 hr PO
 
* Adults: 250-500 mg q 6-12 hr PO (max dose: 4 g/24 hr)
Children: 150 mg/kg/24 hr divided q 6-8 hr IV or IM. Adults: 1-2 g q 6-8 hr IV or IM (max dose: 12 g/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally  eliminated.
* Rash
 
* Eosinophilia
''Drug interaction: ''Probenecid.
 
|-
|-
| '''Chloramphenicol'''
|
|
'''Ceftriaxone  sodium'''
* Gram-positive pathogens
 
* Salmonella
Rocephin. Injection.
* Enterococcus faecium
 
* Bacteroides
* Mycoplasma
* Chlamydia
* Rickettsia
|
|
'''3rd generation cephalosporin active against gram-positive and gram-negative pathogens. No antipseudomonal activity.'''
* Neonates: loading dose of 20 mg/kg followed by
 
* Neonates (postnatal age ≤ 7 days): 25 mg/kg/24 hr q 24 hr IV
Neonates: 50-75 mg/kg q 24 hr IV or IM.
* Neonates (postnatal age > 7 days): 25 mg/kg/24 hr q 24 hr IV (< 2,000 g); 50 mg/kg/24 hr divided q 12 hr IV (> 2,000 g)
 
* Children: 50-75 mg/kg/24 hr divided q 6-8 hr IV or PO
Children: 50-75 mg/kg q 24 hr IV or IM (meningitis: 75 mg/kg dose 1 then 80-100 mg/kg/24 hr divided q 12-24 hr IV or IM).
* Adults: 50 mg/kg/24 hr divided q 6 hr IV or PO (max dose: 4 g/24 hr)
 
Adults: 1-2 g q 24 hr IV or IM (max dose: 4 g/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia). Eliminated via kidney (33-65%) and bile; can cause sludging. Long half-life and dose-dependent protein binding favors q 24 hr rather than q 12 hr dosing. Can add 1% lidocaine for IM injection.
* Gray-baby syndrome
 
* Bone marrow suppression
* Aplastic anemia
|-
|-
| '''Ciprofloxacin'''
|
|
'''Cefuroxime (cefuroxime axetil for oral administration)'''
* P. aeruginosa
 
* Serratia
Ceftin, Kefurox, Zinacef. Injection.
* Enterobacter
 
* Shigella
Suspension: 125 mg/5 mL. Tablet: 125, 250, 500 mg.
* Salmonella
 
* Campylobacter
* N. gonorrhoeae
* H. influenzae
* M. catarrhalis
|
|
'''2nd generation cephalosporin active against S. aureus, ''Streptococcus, H. influenzae, E. coli, M. catarrhalis, Klebsiella, ''and ''Proteus.'''''
* Neonates: 10 mg/kg q 12 hr PO or IV
 
* Children: 15-30 mg/kg/24 hr divided q 12 hr PO or IV
Neonates: 40-100 mg/kg/24 hr divided q 12 hr IV or IM. Children: 200-240 mg/kg/24 hr divided q 8 hr IV or IM; PO
* Adults: 250-750 mg q 12 hr; 200-400 mg IV q 12 hr PO (max dose: 1.5 g/24 hr)
 
administration: 20-30 mg/kg/24 hr divided q 8 hr PO. Adults: 750-1,500 mg q 8 hr IV or IM (max dose: 6 g/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated. Food increases PO bioavailability.
* Tendonitis
 
* Dizziness
''Drug interaction: ''Probenecid.
* Confusion
 
* Crystalluria
* Photosensitivity
|-
|-
| '''Clarithromycin'''
|
|
'''Cephalexin'''
* S. aureus
 
* Streptococcus
Keflex, Keftab. Capsule: 250, 500 mg
* H. influenzae
 
* Legionella
Tablet: 500 mg, 1 g.
* Mycoplasma
 
* C. trachomatis
Suspension: 125 mg/5 mL, 250 mg/5 mL, 100 mg/mL drops.
 
|
|
'''1st generation cephalosporin active against ''S. aureus, Streptococcus, E. coli, Klebsiella, ''and ''Proteus.'''''
* Children: 15 mg/kg/24 hr divided q 12 hr PO
 
* Adults: 250-500 mg q 12 hr PO (max dose: 1 g/24 hr)
Children: 25-100 mg/kg/24 hr divided q 6-8 hr PO. Adults: 250-500 mg q 6 hr PO (max dose: 4 g/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally  eliminated.
* Gastrointestinal distress
 
* Dyspepsia
''Drug interaction: ''Probenecid.
* Nausea
 
* Cramping
|-
|-
| '''Clindamycin'''
|
|
'''Cephradine'''
* Gram-positive aerobic pathogens
 
* Anaerobic cocci except Enterococcus
Velosef
 
Capsule: 250, 500 mg.
 
Suspension: 125 mg/5 mL, 250 mg/5 mL.
 
|
|
'''1st generation cephalosporin active against ''S. aureus, Streptococcus, E. coli, Klebsiella, ''and ''Proteus.'''''
* Neonates (postnatal age ≤ 7 days): 10 mg/kg/24 hr divided q 12 hr IV or IM (≤ 2,000 g); 15 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
 
* Neonates (postnatal age > 7 days): 10 mg/kg/24 hr IV or IM divided q 12 hr (≤ 1,200 g); 15 mg/kg/24 hr divided q 8 hr IV or IM (1,200–2,000 g); 20 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
Children: 50-100 mg/kg/24 hr divided q 6-12 hr PO. Adults: 250-500 mg q 6-12 hr PO (max dose: 4 g/24 hr).
* Children: 10-40 mg/kg/24 hr divided q 6-8 hr IV, IM, or PO
 
* Adults: 150-600 mg q 6-8 hr IV, IM, or PO (max dose: 5 g/24 hr IV or IM or 2 g/24 hr PO)
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally  eliminated.
* Diarrhea
 
* Nausea
''Drug interaction: ''Probenecid.
* Pseudomembranous colitis
 
* Rash
|-
|-
| '''Cloxacillin'''
|
|
'''Chloramphenicol '''Chloromycetin. Injection.  Capsule: 250 mg.
* S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci
 
Ophthalmic, otic solutions. Ointment.
 
|
|
'''Broad-spectrum protein synthesis inhibitor active against many gram-positive and gram-negative bacteria, ''Salmonella, ''vancomycin-resistant  ''Enterococcus  faecium,  Bacteroides, ''other anaerobes, ''Mycoplasma, Chlamydia, ''and ''Rickettsia''; usually inactive against ''Pseudomonas''.'''
* Children: 50-100 mg/kg/24 hr divided q 6 hr PO
 
* Adults: 250-500 mg q 6 hr PO (max dose: 4 g/24 hr)
Neonates: Initial loading dose 20 mg/kg followed 12 hr later by: postnatal age ≤7 days: 25 mg/kg/24 hr q 24 hr IV; 7 days:
 
≤2,000 g: 25 mg/kg/24 hr q 24 hr IV; 2,000 g: 50 mg/kg/24 hr divided q 12 hr IV.
 
Children: 50-75 mg/kg/24 hr divided q 6-8 hr IV or PO (meningitis: 75-100 mg/kg/24 hr IV divided q 6 hr).
 
Adults: 50 mg/kg/24 hr divided q 6 hr IV or PO (max dose: 4 g/24 hr).
 
|
|
''Cautions: ''Gray-baby syndrome (from too-high dose in neonate), bone marrow suppression aplastic anemia (monitor hematocrit, free serum iron).
* Rash
 
* Eosinophilia
''Drug interactions: ''Phenytoin, phenobarbital, rifampin may decrease levels.
 
''Target serum concentrations: ''Peak 20-30 mg/L; trough 5-10 mg/L.
 
 
|-
|-
| '''Trimethoprim-Sulfamethoxazole'''
|
|
'''Ciprofloxacin'''
* Shigella
 
* Legionella
Cipro.
* Nocardia
 
* Chlamydia
Tablet: 100, 250, 500, 750 mg.
* Pneumocystis jirovecii
 
Injection.
 
Ophthalmic solution and ointment. Otic suspension.
 
Oral suspension: 250 and 500 mg/5 mL.
 
|
|
'''Quinolone antibiotic active against ''P. aeruginosa, Serratia, Enterobacter, Shigella, Salmonella, Campylobacter, N. gonorrhoeae, H. influenzae, M. catarrhalis, ''some ''S. aureus, ''and some ''Streptococcus.'''''
* Children: 6-20 mg TMP/kg/24 hr or IV divided q 12 hr PO
 
* Adults: 160 mg TMP q 12 hr PO
Neonates: 10 mg/kg q 12 hr PO or IV.
 
Children: 15-30 mg/kg/24 hr divided q 12 hr PO or IV; cystic fibrosis: 20-40 mg/kg/24 hr divided q 8-12 hr PO or IV.
 
Adults: 250-750 mg q 12 hr; 200-400 mg IV q 12 hr PO (max dose: 1.5 g/24 hr).
 
|
|
''Cautions: ''Concerns of joint destruction in juvenile animals not seen in humans; tendonitis, superinfection, dizziness, confusion, crystalluria, some photosensitivity.
* Rash
 
* Erythema multiforme
''Drug interactions: ''Theophylline; magnesium-, aluminum-, or calcium-containing antacids; sucralfate; probenecid; warfarin; cyclosporine.
* Stevens-Johnson syndrome
 
* Nausea
* Leukopenia
|-
|-
| '''Demeclocycline'''
|
|
'''Clarithromycin'''
* Gram-positive cocci except Enterococcus
 
* Gram-negative bacilli
Biaxin.
* Anaerobes
 
* Borrelia burgdorferi
Tablet: 250, 500 mg.
* Mycoplasma
 
* Chlamydia
Suspension: 125 mg/5 mL, 250 mg/5 mL.
 
|
|
'''Macrolide antibiotic with activity against ''S. aureus, Streptococcus, H. influenzae, Legionella, Mycoplasma, ''and'''
* Children: 8-12 mg/kg/24 hr divided q 6-12 hr PO
 
* Adults: 150 mg PO q 6-8 hr
'''''C.  trachomatis.'''''
 
Children: 15 mg/kg/24 hr divided q 12 hr PO.
 
Adults: 250-500 mg q 12 hr PO (max dose: 1 g/24 hr).
 
|
|
''Cautions: ''Adverse events less than erythromycin; gastrointestinal  upset,  dyspepsia,  nausea, cramping.
* Teeth staining
 
* Photosensitivity
''Drug interactions: ''Same as erythromycin: astemizole  carbamazepine,  terfenadine cyclosporine, theophylline, digoxin, tacrolimus.
* Diabetes insipidus
 
* Nausea
* Vomiting
* Diarrhea
|-
|-
| '''Dicloxacillin'''
|
|
'''Clindamycin'''
* S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci
 
Cleocin.
 
Capsule: 75, 150, 300 mg. Suspension: 75 mg/5 mL. Injection.
 
Topical solution, lotion, and gel. Vaginal cream.
 
|
|
'''Protein synthesis inhibitor active against most gram-positive aerobic and anaerobic cocci except ''Enterococcus.'''''
* Children: 12.5-100 mg/kg/24 hr divided q 6 hr PO
 
* Adults: 125-500 mg q 6 hr PO
Neonates: Postnatal age ≤7 days 200 g; 10 mg/kg/24 hr divided q 12 hr IV or IM; 2,000 g: 15 mg/kg/24 hr divided q 8 hr IV or IM;
 
7 days 1,200 g: 10 mg/kg/24 hr IV or IM divided q 12 hr; 1,200-2,000 g: 15 mg/kg/24 hr divided q 8 hr IV or IM; 2,000 g: 20 mg/kg/24 hr divided q 8 hr IV or IM.
 
Children: 10-40 mg/kg/24 hr divided q 6-8 hr IV, IM, or PO.
 
Adults: 150-600 mg q 6-8 hr IV, IM, or PO (max dose: 5 g/24 hr IV or IM or 2 g/24 hr PO).
 
|
|
''Cautions: ''Diarrhea, nausea, ''Clostridium difficile''–associated colitis, rash. Administer slow IV over 30-60 min. Topically active as an acne treatment.
* Rash
 
* Eosinophilia
|-
|-
| '''Doripenem'''
|
|
'''Cloxacillin  sodium'''
* Gram-positive cocci
 
* Gram-negative bacilli including P. aeruginosa
Tegopen.
* Anaerobes
 
Capsule: 250, 500 mg. Suspension: 125 mg/5 mL.
 
|
|
'''Penicillinase-resistant penicillin active against ''S. aureus ''and other gram-positive cocci except ''Enterococcus ''and coagulase- negative  staphylococci.'''
* Adults: 500 mg q 8 hr IV
 
Children: 50-100 mg/kg/24 hr divided q 6 hr PO. Adults: 250-500 mg q 6 hr PO (max dose: 4 g/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia). Primarily hepatically eliminated; requires dose reduction in renal disease. Food decreases  bioavailability.
* Rash
 
* Eosinophilia
''Drug interaction: ''Probenecid.
 
|-
|-
| '''Doxycycline'''
|
|
'''Co-trimoxazole (trimethoprim- sulfamethoxazole;  TMP-SMZ)'''
* Gram-positive cocci except Enterococcus
 
* Gram-negative bacilli
Bactrim, Cotrim, Septra, Sulfatrim. Tablet: SMZ 400 mg and TMP 80 mg.
* Anaerobes
 
* B. burgdorferi
Tablet DS: SMZ 800 mg and TMP 160 mg. Suspension: SMZ 200 mg and TMP
* Mycoplasma
 
* Chlamydia
40 mg/5 mL. Injection.
 
|
|
'''Antibiotic combination with sequential antagonism of bacterial folate synthesis with broad antibacterial activity: ''Shigella, Legionella, Nocardia, Chlamydia, Pneumocystis jiroveci. ''Dosage based on TMP component.'''
* Children: 2-5 mg/kg/24 hr divided q 12-24 hr PO or IV (max dose: 200 mg/24 hr)
 
* Adults: 100-200 mg/24 hr divided q 12-24 hr PO or IV
Children: 6-20 mg TMP/kg/24 hr or IV divided q 12 hr PO.
 
''Pneumocystis carinii ''pneumonia: 15-20 mg TMP/kg/24 hr divided q 12 hr PO or IV.
 
''P. carinii ''prophylaxis: 5 mg TMP/kg/24 hr or 3 times/wk PO. Adults: 160 mg TMP q 12 hr PO.
 
|
|
''Cautions: ''Drug dosed on TMP (trimethoprim) component. Sulfonamide skin reactions: rash, erythema multiforme,
* Teeth staining
 
* Photosensitivity
Stevens-Johnson syndrome, nausea, leukopenia. Renal and hepatic elimination; reduce dose in renal failure.
* Nausea
 
* Vomiting
''Drug interactions: ''Protein displacement with warfarin, possibly phenytoin, cyclosporine.
* Diarrhea
 
|-
|-
| '''Erythromycin'''
|
|
'''Demeclocycline'''
* Gram-positive organisms
 
* Corynebacterium diphtheriae
Declomycin.
* Mycoplasma pneumoniae
 
Tablet: 150, 300 mg.
 
Capsule: 150 mg.
 
|
|
'''Tetracycline active against most gram-positive cocci except ''Enterococcus'', many gram-negative bacilli, anaerobes, ''Borrelia burgdorferi ''(Lyme disease), ''Mycoplasma, ''and ''Chlamydia.'''''
* Neonates (postnatal age ≤ 7 days): 20 mg/kg/24 hr divided q 12 hr PO
 
* Neonates (postnatal age > 7 days): 20 mg/kg/24 hr divided q 12 hr PO (< 1,200 g); 30 mg/kg/24 hr divided q 8 hr PO (> 1,200 g)
Children: 8-12 mg/kg/24 hr divided q 6-12 hr PO. Adults: 150 mg PO q 6-8 hr.
* Children: Usual max dose 2 g/24 hr. Base: 30-50 mg/kg/24 hr divided q 6-8 hr PO. Estolate: 30-50 mg/kg/24 hr divided q 8-12 hr PO. Stearate: 20-40 mg/kg/24 hr divided q 6 hr PO. Lactobionate: 20-40 mg/kg/24 hr divided q 6-8 hr IV. Gluceptate: 20-50 mg/kg/24 hr divided q 6 hr IV; usual max dose 4 g/24 hr IV
 
* Adults: Base: 333 mg PO q 8 hr; estolate/stearate/base: 250-500 mg q 6 hr PO
Syndrome of inappropriate antidiuretic hormone secretion: 900- 1,200 mg/24 hr or 13-15 mg/kg/24 hr divided q 6-8 hr PO with dose reduction based on response to 600-900 mg/24 hr.
 
|
|
''Cautions: ''Teeth staining, possibly permanent (if administered 8 yr of age) with prolonged use; photosensitivity, diabetes insipidus, nausea, vomiting, diarrhea, superinfections.
* Cramping
 
* Nausea
''Drug interactions: ''Aluminum-, calcium-, magnesium-, zinc- and iron-containing food, milk, dairy products may decrease absorption.
* Vomiting
 
* Diarrhea
* Hypertrophic pyloric stenosis
|-
|-
| '''Gentamicin'''
|
|
'''Dicloxacillin'''
* E. coli
 
* Klebsiella
Dynapen, Pathocil.
* Proteus
 
* Enterobacter
Capsule: 125, 250, 500 mg. Suspension: 62.5 mg/5 mL.
* Serratia
 
* Pseudomonas
|
|
'''Penicillinase-resistant penicillin active against ''S. aureus ''and other gram-positive cocci except ''Enterococcus ''and coagulase- negative  staphylococci.'''
* Neonates (postnatal age ≤ 7 days): 2.5 mg/kg q 12-18 hr IV or IM (< 2,000 g); 2.5 mg/kg q 12 hr IV or IM (> 2,000 g)
 
* Neonates (postnatal age > 7 days): 2.5 mg/kg q 8-12 hr IV or IM (< 2,000 g); 32.5 mg/kg q 8 hr IV or IM (> 2,000 g)
Children: 12.5-100 mg/kg/24 hr divided q 6 hr PO. Adults: 125-500 mg q 6 hr PO.
* Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM; 5-7.5 mg/kg/24 hr IV once daily
 
* Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia). Primarily renally (65%) and bile (30%) elimination. Food may decrease bioavailability.
* Ototoxicity
 
* Nephrotoxicity
''Drug interaction: ''Probenecid.
 
|-
|-
| '''Imipenem-Cilastatin'''
|
|
'''Doripenem '''Doribax. Injection.
* Gram-positive cocci
 
* Gram-negative bacilli including P. aeruginosa
* Anaerobes
|
|
'''Carbapenem antibiotic with broad-spectrum activity against gram-positive cocci and gram-negative bacilli, including'''
* Neonates (postnatal age ≤ 7 days): 20 mg/kg q 18-24 hr IV or IM (< 1,200 g); 40 mg/kg divided q 12 hr IV or IM (> 1,200 g)
 
* Neonates (postnatal age > 7 days): 40 mg/kg q 12 hr IV or IM (< 2,000 g); 60 mg/kg q 8 hr IV or IM (> 2,000 g)
'''''P. aeruginosa ''and anaerobes.'''
* Children: 60-100 mg/kg/24 hr divided q 6-8 hr IV or IM
 
* Adults: 2-4 g/24 hr divided q 6-8 hr IV or IM (max dose: 4 g/24 hr)
Children: dose unknown. Adults: 500 mg q 8 hr IV.
 
|
|
''Cautions: ''-Lactam safety profile; does not undergo hepatic metabolism. Renal elimination (70-75%); dose adjustment for renal failure.
* Rash
 
* Eosinophilia
''Drug interactions: ''Valproic acid, probenecid.
* Nausea
 
* Seizures
|-
|-
| '''Linezolid'''
|
|
'''Doxycycline '''Vibramycin, Doxy. Injection.
* Staphylococcus
 
* Streptococcus
Capsule: 50, 100 mg.
* E. faecium
 
* Enterococcus faecalis
Tablet: 50, 100 mg. Suspension: 25 mg/5 mL. Syrup: 50 mg/5 mL.
 
|
|
'''Tetracycline antibiotic active against most gram-positive cocci except ''Enterococcus, ''many gram-negative bacilli, anaerobes,'''
* Children: 10 mg/kg q 12 hr IV or PO
 
* Adults: Pneumonia: 600 mg q 12 hr IV or PO
'''''B. burgdorferi ''(Lyme disease), ''Mycoplasma, ''and ''Chlamydia.'''''
 
Children: 2-5 mg/kg/24 hr divided q 12-24 hr PO or IV (max dose: 200  mg/24  hr).
 
Adults: 100-200 mg/24 hr divided q 12-24 hr PO or IV.
 
|
|
''Cautions: ''Teeth staining, possibly permanent (8 yr of age) with prolonged use; photosensitivity, nausea, vomiting, diarrhea, superinfections.
* Bone marrow suppression
 
* Pseudomembranous colitis
''Drug interactions: ''Aluminum-, calcium-, magnesium-, zinc-, iron-, kaolin-, and pectin-containing products, food, milk, dairy products may decrease absorption. Carbamazepine, rifampin, barbiturates may decrease half-life.
* Nausea
 
* Diarrhea
* Headache
|-
|-
| '''Loracarbef'''
|
|
'''Erythromycin'''
* S. aureus
 
* Streptococcus
E-Mycin, Ery-Tab, Ery-C, Ilosone. Estolate 125, 500 mg.
* H. influenzae
 
* M. catarrhalis
Tablet EES: 200 mg.
* E. coli
 
* Klebsiella
Tablet base: 250, 333, 500 mg. Suspension: estolate 125 mg/5 mL,
* Proteus
 
250 mg/5 mL, EES 200 mg/5 mL, 400 mg/5 mL.
 
Estolate drops: 100 mg/mL. EES drops:
 
100 mg/2.5 mL. Available in combination with sulfisoxazole (Pediazole), dosed on erythromycin content.
 
|
|
'''Bacteriostatic macrolide antibiotic most active against gram- positive organisms, ''Corynebacterium diphtheriae, ''and ''Mycoplasma  pneumoniae.'''''
* Children: 30 mg/kg/24 hr divided q 12 hr PO (max dose: 2 g)
 
* Adults: 200-400 mg q 12 hr PO (max dose: 800 mg/24 hr)
Neonates: Postnatal age ≤7 days: 20 mg/kg/24 hr divided q 12 hr PO;
 
7 days 1,200 g: 20 mg/kg/24 hr divided q 12 hr PO; 1,200 g:
 
30 mg/kg/24 hr divided q 8 hr PO (give as 5 mg/kg/dose q 6 hr to
 
improve feeding intolerance). Children: Usual max dose 2 g/24 hr.
 
Base: 30-50 mg/kg/24 hr divided q 6-8 hr PO. Estolate: 30-50 mg/kg/24 hr divided q 8-12 hr PO. Stearate: 20-40 mg/kg/24 hr divided q 6 hr PO. Lactobionate: 20-40 mg/kg/24 hr divided q 6-8 hr IV.
 
Gluceptate: 20-50 mg/kg/24 hr divided q 6 hr IV; usual max dose 4 g/24 hr IV.
 
Adults: Base: 333 mg PO q 8 hr; estolate/stearate/base: 250-500 mg q 6 hr PO.
 
|
|
''Cautions: ''Motilin agonist leading to marked abdominal cramping, nausea, vomiting, diarrhea. Associated with hypertrophic pyloric stenosis in young infants. Many different salts with questionable tempering of gastrointestinal adverse events. Rare cardiac toxicity with IV use. Dose of salts differ. Topical formulation for treatment of acne.
* Rash
 
* Eosinophilia
''Drug interactions: ''Antagonizes hepatic CYP 3A4 activity:  astemizole,  carbamazepine, terfenadine,  cyclosporine,  theophylline, digoxin,  tacrolimus,  carbamazepine.
 
|-
|-
| '''Meropenem'''
|
|
'''Gentamicin '''Garamycin. Injection.
* Gram-positive cocci
 
* Gram-negative bacilli including P. aeruginosa
Ophthalmic solution, ointment, topical cream.
* Anaerobes
 
|
|
'''Aminoglycoside antibiotic active against gram-negative bacilli, especially ''E. coli, Klebsiella, Proteus, Enterobacter, Serratia, ''and ''Pseudomonas.'''''
* Children: 60 mg/kg/24 hr divided q 8 hr IV
 
* Adults: 1.5-3 g q 8 hr IV
Neonates: Postnatal age ≤7 days 1,200-2,000 g: 2.5 mg/kg q
 
12-18 hr IV or IM; 2,000 g: 2.5 mg/kg q 12 hr IV or IM; postnatal
 
age 7 days 1,200-2,000 g: 2.5 mg/kg q 8-12 hr IV or IM;
 
2,000 g: 2.5 mg/kg q 8 hr IV or IM.
 
Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM. Alternatively
 
may administer 5-7.5 mg/kg/24 hr IV once daily. Intrathecal: Preservative-free preparation for intraventricular or
 
intrathecal use: neonate: 1 mg/24 hr; children: 1-2 mg/24 hr IT; adults: 4-8 mg/24 hr.
 
Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM.
 
|
|
''Cautions: ''Anaerobes, ''S. pneumoniae, ''and other ''Streptococcus ''are resistant. May cause ototoxicity and nephrotoxicity. Monitor renal function. Drug eliminated renally. Administered IV over 30-60 min.
* Rash
 
* Eosinophilia
''Drug interactions: ''May potentiate other ototoxic and nephrotoxic drugs.
 
''Target serum concentrations: ''Peak 6-12 mg/L; trough 2 mg/L with intermittent daily dose regimens only.
 
|-
|-
| '''Metronidazole'''
|
|
'''Imipenem-cilastatin'''
* Anaerobes
 
Primaxin. Injection.
 
|
|
'''Carbapenem antibiotic with broad-spectrum activity against gram-positive cocci and gram-negative bacilli, including'''
* Neonates (postnatal age ≤ 7 days): 7.5 mg/kg 48 hr PO or IV (< 1,200 g); 7.5 mg/kg/24 hr q 24 hr PO or IV (1,200–2,000 g); 15 mg/kg/24 hr divided q 12 hr PO or IV (> 2,000 g)
 
* Neonates (postnatal age > 7 days): 5 mg/kg/24 hr divided q 12 hr PO or IV (< 2,000 g); 30 mg/kg/24 hr divided q 12 hr PO or IV (> 2,000 g)
'''''P. aeruginosa ''and anaerobes. No activity against'''
* Children: 30 mg/kg/24 hr divided q 6-8 hr PO or IV
 
* Adults: 30 mg/kg/24 hr divided q 6 hr PO or IV (max dose: 4 g/24 hr)
'''''Stenotrophomonas  maltophilia.'''''
 
Neonates: Postnatal age ≤7 days 1,200 g: 20 mg/kg q 18-24 hr IV or IM; 1,200 g: 40 mg/kg divided q 12 hr IV or IM; postnatal age
 
7 days 1,200-2,000 g: 40 mg/kg q 12 hr IV or IM; 2,000 g: 60 mg/kg q 8 hr IV or IM.
 
Children: 60-100 mg/kg/24 hr divided q 6-8 hr IV or IM.
 
Adults: 2-4 g/24 hr divided q 6-8 hr IV or IM (max dose: 4 g/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia), nausea, seizures. Cilastatin possesses no antibacterial activity; reduces renal imipenem metabolism. Primarily renally eliminated.
* Dizziness
 
* Seizures
''Drug interaction: ''Possibly ganciclovir.
* Metallic taste
 
* Nausea
* Hypoprothrombinemia
* Disulfiram-like reaction
|-
|-
| '''Mezlocillin'''
|
|
'''Linezolid'''
* E. coli
 
* Enterobacter
Zyvox.
* Serratia
 
* Bacteroides
Tablet: 400, 600 mg.
 
Oral suspension: 100 mg/5 mL. Injection: 100 mg/5 mL.
 
|
|
'''Oxazolidinone  antibiotic  active  against  gram-positive  cocci (especially  drug-resistant  organisms),  including ''Staphylococcus, Streptococcus, E. faecium, ''and ''Enterococcus faecalis. ''Interferes with protein synthesis by binding to 50S ribosome  subunit.'''
* Neonates (postnatal age ≤ 7 days): 150 mg/kg/24 hr divided q 12 hr IV
 
* Neonates (postnatal age > 7 days): 225 mg/kg divided q 8 hr IV
Children: 10 mg/kg q 12 hr IV or PO.
* Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV
 
* Adults: 2-4 g/dose q 4-6 hr IV (max dose: 12 g/24 hr)
Adults: Pneumonia: 600 mg q 12 hr IV or PO; skin infections: 400 mg q 12 hr IV or PO.
 
|
|
''Adverse events: ''Myelosuppression, pseudomembranous  colitis,  nausea,  diarrhea, headache.
* Rash
 
* Eosinophilia
''Drug interaction: ''Probenecid.
* Liver transaminases elevation
 
|-
|-
| '''Mupirocin'''
|
|
'''Loracarbef'''
* Staphylococcus
 
* Streptococcus
Lorabid.
 
Capsule: 200 mg.
 
Suspension: 100 mg/5 mL, 200 mg/5 mL.
 
|
|
'''Carbacephem very closely related to cefaclor (2nd generation cephalosporin) active against ''S. aureus, Streptococcus, H. influenzae, M. catarrhalis, E. coli, Klebsiella, ''and ''Proteus.'''''
* Topical application to the skin 2-4 times per day
 
Children: 30 mg/kg/24 hr divided q 12 hr PO (max dose: 2 g). Adults: 200-400 mg q 12 hr PO (max dose: 800 mg/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally  eliminated.
* Itching
 
''Drug interaction: ''Probenecid.
 
|-
|-
| '''Nafcillin'''
|
|
'''Meropenem '''Merrem. Injection.
* S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci
 
|
|
'''Carbapenem antibiotic with broad-spectrum activity against gram-positive cocci and gram-negative bacilli, including ''P. aeruginosa ''and anaerobes. No activity against ''Stenotrophomonas  maltophilia.'''''
* Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr divided q 12 hr IV or IM (< 2,000 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
 
* Neonates (postnatal age > 7 days): 75 mg/kg/q 8 hr IV (< 2,000 g); 100 mg/kg divided q 6-8 hr IV (> 2,000 g)
Children: 60 mg/kg/24 hr divided q 8 hr IV meningitis: 120 mg/ kg/24 hr (max dose: 6 g/24 hr) q 8 hr IV.
* Children: 100-200 mg/kg/24 hr divided q 4-6 hr IV
 
* Adults: 4-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr)
Adults: 1.5-3 g q 8 hr IV.
 
|
|
''Cautions: ''-Lactam safety profile; appears to possess less CNS excitation than imipenem. 80% renal elimination.
* Rash
 
* Eosinophilia
''Drug interaction: ''Probenecid.
* Phlebitis
 
* Neutropenia
|-
|-
| '''Nalidixic acid'''
|
|
'''Metronidazole'''
* E. coli
 
* Enterobacter
Flagyl, Metro-IV, generic. Topical gel, vaginal gel. Injection.
* Klebsiella
 
* Proteus
Tablet: 250, 500 mg.
 
|
|
'''Highly effective in the treatment of infections due to anaerobes.'''
* Children: 50-55 mg/kg/24 hr divided q 6 hr PO; suppressive therapy 25-33 mg/kg/24 hr divided q 6-8 hr PO
 
* Adults: 1 g q 6 hr PO; suppressive therapy: 500 mg q 6 hr PO
Neonates: 1,200 g: 7.5 mg/kg 48 hr PO or IV; postnatal age ≤7 days 1,200-2,000 g: 7.5 mg/kg/24 hr q 24 hr PO or IV; 2,000 g: 15 mg/ kg/24 hr divided q 12 hr PO or IV; postnatal age 7 days
 
1,200-2,000 g: 15 mg/kg/24 hr divided q 12 hr PO or IV; 2,000 g: 30 mg/kg/24 hr divided q 12 hr PO or IV.
 
Children: 30 mg/kg/24 hr divided q 6-8 hr PO or IV.
 
Adults: 30 mg/kg/24 hr divided q 6 hr PO or IV (max dose: 4 g/24 hr).
 
|
|
''Cautions: ''Dizziness, seizures, metallic taste, nausea, disulfiram-like reaction with alcohol. Administer IV slow over 30-60 min. Adjust dose with hepatic impairment.
* Vertigo
 
* Dizziness
''Drug interactions: ''Carbamazepine, rifampin, phenobarbital may enhance metabolism; may increase levels of warfarin, phenytoin, lithium.
* Rash
 
|-
|-
| '''Neomycin'''
|
|
'''Mezlocillin sodium'''
* Gastrointestinal flora
 
Mezlin. Infection.
 
|
|
<center>'''Extended-spectrum penicillin active against ''E. coli, Enterobacter, Serratia, ''and ''Bacteroides; ''limited antipseudomonal activity. '''Neonates: Postnatal age ≤7 days: 150 mg/kg/24 hr divided q 12 hr IV;</center>
* Infants: 50 mg/kg/24 hr divided q 6 hr PO
 
* Children: 50-100 mg/kg/24 hr divided q 6-8 hr PO
7 days: 225 mg/kg divided q 8 hr IV.
* Adults: 500-2,000 mg/dose q 6-8 hr PO
 
Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV; cystic fibrosis
 
300-450 mg/kg/24 hr IV.
 
Adults: 2-4 g/dose q 4-6 hr IV (max dose: 12 g/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia); painful given intramuscularly; each gram contains 1.8 mEq sodium. Interferes with platelet aggregation with high doses; increases noted in liver function test results. Renally eliminated. Inactivated by
* Cramping
 
* Diarrhea
<center>-lactamase enzyme.</center>
* Rash
 
* Ototoxicity
''Drug interaction: ''Probenecid.
* Nephrotoxicity
 
|-
|-
| '''Nitrofurantoin'''
|
|
'''Mupirocin '''Bactroban. Ointment.
* Gram-positive pathogens
 
* Gram-negative pathogens
|
|
'''Topical antibiotic active against ''Staphylococcus ''and'''
* Children: 5-7 mg/kg/24 hr divided q 6 hr PO (max dose: 400 mg/24 hr); suppressive therapy 1-2.5 mg/kg/24 hr divided q 12-24 hr PO (max dose: 100 mg/24 hr)
 
* Adults: 50-100 mg/24 hr divided q 6 hr PO
'''''Streptococcus.'''''
 
Topical application: Nasal (eliminate nasal carriage) and to the skin 2-4 times per day.
 
|
|
''Caution: ''Minimal systemic absorption as drug metabolized within the skin.
* Vertigo
 
* Dizziness
* Rash
* Jaundice
* Interstitial pneumonitis
|-
|-
| '''Ofloxacin'''
|
|
'''Nafcillin sodium '''Nafcil, Unipen. Injection. Capsule: 250 mg.
* Gram-positive pathogens
 
* Gram-negative pathogens
Tablet: 500 mg.
* Anaerobes
 
* Chlamydia trachomatis
|
|
'''Penicillinase-resistant penicillin active against ''S. aureus ''and other gram-positive cocci, except ''Enterococcus ''and coagulase-negative  staphylococci.'''
* Child (&lt; 12 yr): Conjunctivitis: 1-2 drops in affected eye(s) q 2-4 hr for 2 days, then 1-2 drops qid for 5 days. Corneal ulcers: 1-2 drops q 30 min while awake and at 4 hours at night for 2 days, then 1-2 drops hourly for 5 days while awake, then 1-2 drops q 6 hr for 2 days. Otitis externa: 5 drops into affected ear bid for 10 days
 
* Child (&gt; 12 yr) and adults: Ophthalmic solution doses same as for younger children. Otitis externa: 10 drops bid for 10–14 days as for younger children
Neonates: Postnatal age ≤7 days 1,200-2,000 g: 50 mg/kg/24 hr divided q 12 hr IV or IM; 2,000 g: 75 mg/kg/24 hr divided q 8 hr IV or IM; postnatal age 7 days 1,200-2,000 g: 75 mg/kg/q 8 hr;
 
2,000 g: 100 mg/kg divided q 6-8 hr IV (meningitis: 200 mg/ kg/24 hr divided q 6 hr IV).
 
Children: 100-200 mg/kg/24 hr divided q 4-6 hr IV.
 
Adults: 4-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia), phlebitis; painful given intramuscularly; oral absorption highly variable and erratic (not recommended).
* Burning
 
* Stinging
''Adverse effect: ''Neutropenia.
* Eye redness
 
* Dizziness
|-
|-
| '''Oxacillin'''
|
|
'''Nalidixic acid'''
* S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci
 
NegGram.
 
Tablet: 250, 500, 1,000 mg. Suspension: 250 mg/5 mL.
 
|
|
'''1st generation quinolone effective for short-term treatment of lower urinary tract infections caused by ''E. coli, Enterobacter, Klebsiella, ''and ''Proteus.'''''
* Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr divided q 12 hr IV (&lt; 2,000 g); 75 mg/kg/24 hr IV divided q 8 hr IV (&gt; 2,000 g)
 
* Neonates (postnatal age &gt; 7 days): 50 mg/kg/24 hr IV divided q 12 hr IV (&lt; 1,200 g); 75 mg/kg/24 hr divided q 8 hr IV (1,200–2,000 g); 100 mg/kg/24 hr IV divided q 6 hr IV (&gt; 2,000 g)
Children: 50-55 mg/kg/24 hr divided q 6 hr PO; suppressive therapy 25-33 mg/kg/24 hr divided q 6-8 hr PO.
* Infants: 100-200 mg/kg/24 hr divided q 4-6 hr IV
 
* Children: PO 50-100 mg/kg/24 hr divided q 4-6 hr IV
Adults: 1 g q 6 hr PO; suppressive therapy: 500 mg q 6 hr PO.
* Adults: 2-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr)
 
|
|
''Cautions: ''Vertigo, dizziness, rash. Not for use in systemic infections.
* Rash
 
* Eosinophilia
''Drug interactions: ''Liquid antacids.
* Neutropenia
 
|-
|-
| '''Penicillin G'''
|
|
'''Neomycin sulfate '''Mycifradin, generic. Tablet: 500 mg.
* S. pneumoniae
 
* Group A Streptococcus
Topical cream, ointment. Solution: 125 mg/5 mL.
* N. gonorrhoeae
 
* N. meningitidis
|
|
'''Aminoglycoside antibiotic used for topical application or orally before surgery to decrease gastrointestinal flora (nonabsorbable) and  hyperammonemia.'''
* Neonates (postnatal age ≤ 7 days): 50,000 units/kg/24 hr divided q 12 hr IV or IM (&lt; 2,000 g); 75,000 units/kg/24 hr divided q 8 hr IV or IM (&gt; 2,000 g)
 
* Neonates (postnatal age &gt; 7 days): 50,000 units/kg/24 hr divided q 12 hr IV (&lt; 1,200 g); 75,000 units/kg/24 hr q 8 hr IV (1,200–2,000 g); 100,000 units/kg/24 hr divided q 6 hr IV (&gt; 2,000 g)
Infants: 50 mg/kg/24 hr divided q 6 hr PO. Children: 50-100 mg/kg/24 hr divided q 6-8 hr PO. Adults: 500-2,000 mg/dose q 6-8 hr PO.
* Children: 100,000-250,000 units/kg/24 hr divided q 4-6 hr IV or IM (max dose: 400,000 units/kg/24 hr)
 
* Adults: 2-24 million units/24 hr divided q 4-6 hr IV or IM
|
|
''Cautions: ''In patients with renal dysfunction because small amount absorbed may accumulate.
* Rash
 
* Eosinophilia
''Adverse events: ''Primarily related to topical application, abdominal cramps, diarrhea, rash. Aminoglycoside ototoxicity and nephrotoxicity if absorbed.
* Allergy
 
* Seizures
|-
|-
| '''Penicillin G, benzathine'''
|
|
'''Nitrofurantoin'''
* Group A Streptococcus
 
Furadantin, Furan, Macrodantin. Capsule: 50, 100 mg.
 
Extended-release capsule: 100 mg. Macrocrystal: 50, 100 mg. Suspension: 25 mg/5 mL.
 
|
|
'''Effective in the treatment of lower urinary tract infections caused by gram-positive and gram-negative pathogens.'''
* Neonates: 50,000 units/kg IM once
 
* Children: 300,000-1.2 million units/kg q 3-4 wk IM (max dose: 1.2-2.4 million units/dose)
Children: 5-7 mg/kg/24 hr divided q 6 hr PO (max dose:
* Adults: 1.2 million units IM q 3-4 wk
 
400 mg/24 hr); suppressive therapy 1-2.5 mg/kg/24 hr divided q 12-24 hr PO (max dose: 100 mg/24 hr).
 
Adults: 50-100 mg/24 hr divided q 6 hr PO.
 
|
|
''Cautions: ''Vertigo, dizziness, rash, jaundice, interstitial pneumonitis. Do not use with moderate to severe renal dysfunction.
* Rash
 
* Eosinophilia
''Drug interactions: ''Liquid antacids.
* Allergy
 
|-
|-
| '''Penicillin G, procaine'''
|
|
'''Ofloxacin'''
* Gram-positive pathogens
 
Ocuflox 0.3% ophthalmic solution: 1, 5,
 
<center>10 mL.</center>
 
Floxin 0.3% otic solution: 5, 10 mL.
 
|
|
'''Quinolone antibiotic for treatment of conjunctivitis or corneal ulcers (ophthalmic solution) and otitis externa or chronic suppurative otitis media (otic solution) caused by susceptible gram-positive, gram-negative, anaerobic bacteria, or ''Chlamydia  trachomatis.'''''
* Neonates: 50,000 units/kg/24 hr IM
 
* Children: 25,000-50,000 units/kg/24 hr IM for 10 days (max dose: 4.8 million units/dose)
''Child ''''1-12 yr:''
* Adults: 0.6-4.8 million units q 12-24 hr IM
 
Conjunctivitis: 1-2 drops in affected eye(s) q 2-4 hr for 2 days, then
 
1-2 drops qid for 5 days.
 
Corneal ulcers: 1-2 drops q 30 min while awake and at 4 hours at night for 2 days, then 1-2 drops hourly for 5 days while awake, then 1-2 drops q 6 hr for 2 days.
 
Otitis externa (otic solution): 5 drops into affected ear bid for 10 days.
 
Chronic suppurative otitis media: treat for 14 days.
 
''Child ''''12 yr and adults: ''Ophthalmic solution doses same as for younger children. Otitis externa (otic solution): Use 10 drops bid for 10 or 14 days as for younger children.
 
|
|
''Adverse events: ''Burning, stinging, eye redness (ophthalmic solution), dizziness with otic solution if not warmed.
* Rash
 
* Eosinophilia
* Allergy
|-
|-
| '''Penicillin V'''
|
|
'''Oxacillin sodium '''Prostaphlin. Injection.
* S. pneumoniae
 
* N. gonorrhoeae
Capsule: 250, 500 mg. Suspension: 250 mg/5 mL.
* N. meningitidis
 
|
|
'''Penicillinase-resistant penicillin active against ''S. aureus ''and other gram-positive cocci, except ''Enterococcus ''and coagulase-negative  staphylococci.'''
* Children: 25-50 mg/kg/24 hr divided q 4-8 hr PO
 
* Adults: 125-500 mg q 6-8 hr PO (max dose: 3 g/24 hr)
Neonates: Postnatal age ≤7 days 1,200-2,000 g: 50 mg/kg/24 hr divided q 12 hr IV; 2,000 g: 75 mg/kg/24 hr IV divided q 8 hr IV; postnatal age 7 days 1,200 g: 50 mg/kg/24 hr IV divided q 12 hr IV; 1,200-2,000 g: 75 mg/kg/24 hr divided q 8 hr IV; 2,000 g:
 
100 mg/kg/24 hr IV divided q 6 hr IV.
 
Infants: 100-200 mg/kg/24 hr divided q 4-6 hr IV. Children: PO 50-100 mg/kg/24 hr divided q 4-6 hr IV.
 
Adults: 2-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia).
* Rash
 
* Eosinophilia
Moderate oral bioavailability (35-65%). Primarily renally eliminated.
* Allergy
 
''Drug interaction: ''Probenecid.
 
''Adverse effect: ''Neutropenia.
 
|-
|-
| '''Piperacillin'''
|
|
'''Penicillin G '''Injection. Tablets.
* E. coli
 
* Enterobacter
* Serratia
* P. aeruginosa
* Bacteroides
|
|
'''Penicillin active against most gram-positive cocci; ''S. pneumoniae ''(resistance is increasing), group A streptococcus, and some gram-negative bacteria  (e.g.,  ''N. gonorrhoeae,  N.  meningitidis'').'''
* Neonates (postnatal age ≤ 7 days): 150 mg/kg/24 hr divided q 8-12 hr IV
 
* Neonates (postnatal age &gt; 7 days): 200 mg/kg divided q 6-8 hr IV
Neonates: Postnatal age ≤7 days 1,200-2,000 g: 50,000 units/ kg/24 hr divided q 12 hr IV or IM (meningitis: 100,000 units/
* Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV
 
* Adults: 2-4 g/dose q 4-6 hr (max dose: 24 g/24 hr) IV
kg/24 hr divided q 12 hr IV or IM); 2,000 g: 75,000 units/kg/24 hr divided q 8 hr IV or IM (meningitis: 150,000 units/kg/24 hr divided  q 8 hr IV or IM); postnatal age 7 days ≤1,200 g: 50,000 units/ kg/24 hr divided q 12 hr IV (meningitis: 100,000 units/kg/24 hr divided q 12 hr IV); 1,200-2,000 g: 75,000 units/kg/24 hr q 8 hr IV (meningitis: 225,000 units/kg/24 hr divided q 8 hr IV); 2,000 g: 100,000 units/kg/24 hr divided q 6 hr IV (meningitis: 200,000 units/ kg/24 hr divided q 6 hr IV).
 
Children: 100,000-250,000 units/kg/24 hr divided q 4-6 hr IV or IM (max dose: 400,000 units/kg/24 hr).
 
Adults: 2-24 million units/24 hr divided q 4-6 hr IV or IM.
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia), allergy, seizures with excessive doses particularly in patients with marked renal disease. Substantial pathogen resistance. Primarily renally eliminated.
* Rash
 
* Eosinophilia
''Drug interaction: ''Probenecid.
* Serum sickness-like reaction
 
|-
|-
| '''Piperacillin-Tazobactam'''
|
|
'''Penicillin G, benzathine'''
* S. aureus
 
* H. influenzae
Bicillin. Injection.
* E. coli
 
* Enterobacter
* Serratia
* Acinetobacter
* P. aeruginosa
* Bacteroides
|
|
'''Long-acting repository form of penicillin effective in the treatment of infections responsive to persistent, low penicillin concentrations (1-4 wk), e.g., group A streptococcus pharyngitis, rheumatic fever prophylaxis.'''
* Children: 300-400 mg/kg/24 hr divided q 6-8 hr IV or IM
 
* Adults: 3.375 g q 6-8 hr IV or IM
Neonates 1,200 g: 50,000 units/kg IM once.
 
Children: 300,000-1.2 million units/kg q 3-4 wk IM (max dose:
 
1.2-2.4 million units/dose).
 
Adults: 1.2 million units IM q 3-4 wk.
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia), allergy. Administer by IM injection only. Substantial pathogen resistance. Primarily renally eliminated.
* Rash
 
* Eosinophilia
''Drug interaction: ''Probenecid.
 
|-
|-
| '''Quinupristin-Dalfopristin'''
|
|
'''Penicillin G, procaine'''
* E. faecium, vancomycin-resistant
 
* S. aureus, methicillin-resistant
Crysticillin. Injection.
 
|
|
'''Repository form of penicillin providing low penicillin concentrations for 12 hr.'''
* Children and adults: 7.5 mg/kg q 8 hr IV
 
Neonates 1,200 g: 50,000 units/kg/24 hr IM.
 
Children: 25,000-50,000 units/kg/24 hr IM for 10 days (max dose:
 
4.8 million units/dose).
 
Gonorrhea: 100,000 units/kg (max dose: 4.8 million units/24 hr) IM once with probenecid 25 mg/kg (max dose: 1 g)
 
Adults: 0.6-4.8 million units q 12-24 hr IM.
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia) allergy. Administer by IM injection only. Substantial pathogen resistance. Primarily renally eliminated.
* Pain
 
* Edema
''Drug interaction: ''Probenecid.
* Phlebitis
 
* Nausea
* Diarrhea
|-
|-
| '''Sulfadiazine'''
|
|
'''Penicillin V'''
* E. coli
 
* P. mirabilis
Pen VK, V-Cillin K.
* Klebsiella
 
Tablet: 125, 250, 500 mg.
 
Suspension: 125 mg/5 mL, 250 mg/5 mL.
 
|
|
'''Preferred oral dosing form of penicillin, active against most gram-positive cocci; ''S. pneumoniae ''(resistance is increasing), other ''Streptococcus, ''and some gram-negative bacteria (e.g.,'''
* Neonates: 100 mg/kg/24 hr divided q 12 hr PO with pyrimethamine 1 mg/kg/24 hr PO with folinic acid
 
* Children: 120-200 mg/kg/24 hr divided q 6 hr PO with pyrimethamine 2 mg/kg/24 hr divided q 12 hr PO ≥3 days then 1 mg/kg/24 hr (max dose: 25 mg/24 hr) with folinic acid
'''''N. gonorrhoeae, N. meningitidis'').'''
 
Children: 25-50 mg/kg/24 hr divided q 4-8 hr PO. Adults: 125-500 mg q 6-8 hr PO (max dose: 3 g/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia), allergy, seizures with excessive doses particularly in patients with renal disease. Substantial pathogen resistance. Primarily renally eliminated. Inactivated by penicillinase.
* Rash
 
* Stevens-Johnson syndrome
''Drug interaction'': Probenecid.
* Nausea
 
* Leukopenia
* Crystalluria
|-
|-
| '''Sulfamethoxazole'''
|
|
'''Piperacillin '''Pipracil. Injection.
* Bacteria associated with otitis media, chronic bronchitis, and lower urinary tract infections
 
|
|
'''Extended-spectrum penicillin active against ''E. coli, Enterobacter, Serratia, P. aeruginosa, ''and ''Bacteroides.'''''
* Children: 50-60 mg/kg/24 hr divided q 12 hr PO
 
* Adults: 1 g/dose q 12 hr PO (max dose: 3 g/24 hr)
Neonates: Postnatal age ≤7 days 150 mg/kg/24 hr divided q 8-12 hr IV; 7 days; 200 mg/kg divided q 6-8 hr IV.
 
Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV; cystic fibrosis: 350-500 mg/kg/24 hr IV.
 
Adults: 2-4 g/dose q 4-6 hr (max dose: 24 g/24 hr) IV.
 
|
|
''Cautions'': -Lactam safety profile (rash, eosinophilia); painful given intramuscularly; each gram contains 1.9 mEq sodium. Interferes with platelet aggregation/serum sickness-like reaction with high doses; increases in liver function tests. Renally eliminated. Inactivated by penicillinase.
* Rash
 
* Stevens-Johnson syndrome
''Drug interaction: ''Probenecid.
* Nausea
 
* Leukopenia
* Crystalluria
|-
|-
| '''Sulfisoxazole'''
|
|
'''Piperacillin-tazobactam'''
* Bacteria associated with otitis media, chronic bronchitis, and lower urinary tract infections
 
Zosyn. Injection.
 
|
|
'''Extended-spectrum penicillin (piperacillin) combined with a'''
* Children: 120-150 mg/kg/24 hr divided q 4-6 hr PO (max dose: 6 g/24 hr)
 
* Adults: 4-8 g/24 hr divided q 4-6 hr PO
β-lactamase inhibitor (tazobactam) active against ''S. aureus, H. influenzae, E. coli, Enterobacter, Serratia, Acinetobacter, P. aeruginosa, ''and ''Bacteroides.'''''
 
Children: 300-400 mg/kg/24 hr divided q 6-8 hr IV or IM. Adults: 3.375 g q 6-8 hr IV or IM.
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia); painful given intramuscularly; each gram contains 1.9 mEq sodium.
* Rash
 
* Stevens-Johnson syndrome
Interferes with platelet aggregation, serum sickness–like reaction with high doses, increases in liver function test results. Renally eliminated.
* Nausea
 
* Leukopenia
''Drug interaction: ''Probenecid.
* Crystalluria
 
|-
|-
| '''Ticarcillin'''
|
|
'''Quinupristin/dalfopristin'''
* E. coli
 
* Enterobacter
Synercid.
* Serratia
 
* P. aeruginosa
IV injection: powder for reconstitution, 10 mL contains 150 mg quinupristin,
* Bacteroides
 
<center>350 mg dalfopristin.</center>
 
|
|
'''Streptogramin antibiotic (quinupristin) active against vancomycin-resistant ''E. faecium ''(VRE) and methicillin- resistant ''S. aureus ''(MRSA)''. ''Not active against ''E. faecalis.'''''
* Neonates (postnatal age ≤ 7 days): 150 mg/kg/24 hr divided q 8-12 hr IV
 
* Neonates (postnatal age &gt; 7 days): 150 mg/kg/24 hr divided q 8-12 hr IV (&lt; 1,200 g); 150 mg/kg/24 hr divided q 12 hr IV (1,200–2,000 g); 300 mg/kg/24 hr divided q 6-8 hr IV (&gt; 2,000 g)
Children and adults: VRE: 7.5 mg/kg q 8 hr IV for VRE; skin infections:
* Children: 200-400 mg/kg/24 hr divided q 4-6 hr IV
 
* Adults: 2-4 g/dose q 4-6 hr IV (max dose: 24 g/24 hr)
7.5 mg/kg q 12 hr IV.
 
|
|
''Adverse events: ''Pain, edema, or phlebitis at injection site, nausea, diarrhea.
* Rash
 
* Eosinophilia
''Drug interactions: ''Synercid is a potent inhibitor of CYP 3A4.
* Liver transaminases elevation
 
|-
|-
| '''Ticarcillin-Clavulanate'''
|
|
'''Sulfadiazine'''
* S. aureus
 
* H. influenzae
Tablet: 500 mg.
* Enterobacter
 
* E. coli
* Serratia
* P. aeruginosa
* Acinetobacter
* Bacteroides
|
|
'''Sulfonamide antibiotic primarily indicated for the treatment of lower urinary tract infections due to ''E. coli, P. mirabilis, ''and ''Klebsiella.'''''
* Children: 280-400 mg/kg/24 hr q 4-8 hr IV or IM
 
* Adults: 3.1 g q 4-8 hr IV or IM (max dose: 18-24 g/24 hr)
Toxoplasmosis:
 
Neonates: 100 mg/kg/24 hr divided q 12 hr PO with pyrimethamine 1 mg/kg/24 hr PO (with folinic acid).
 
Children: 120-200 mg/kg/24 hr divided q 6 hr PO with pyrimethamine 2 mg/kg/24 hr divided q 12 hr PO ≥3 days then 1 mg/kg/24 hr (max dose: 25 mg/24 hr) with folinic acid.
 
Rheumatic fever prophylaxis: ≤30 kg: 500 mg/24 hr q 24 hr PO;
 
30 kg: 1 g/24 hr q 24 hr PO.
 
|
|
''Cautions: ''Rash, Stevens-Johnson syndrome, nausea, leukopenia, crystalluria. Renal and hepatic elimination; avoid use with renal disease. Half-life  ∼10  hr.
* Rash
 
* Eosinophilia
''Drug interactions: ''Protein displacement with warfarin, phenytoin, methotrexate.
* Liver transaminases elevation
 
|-
|-
| '''Tigecycline'''
|
|
'''Sulfamethoxazole'''
* Enterobacteriaceae including ESBL producers
 
* Streptococcus
Gantanol. Tablet: 500 mg.
* Staphylococcus
 
* Anaerobes
Suspension: 500 mg/5 mL.
 
|
|
'''Sulfonamide antibiotic used for the treatment of otitis media, chronic bronchitis, and lower urinary tract infections due to susceptible bacteria.'''
* Adults: 100 mg loading dose followed by 50 mg q 12 hr IV
 
Children: 50-60 mg/kg/24 hr divided q 12 hr PO. Adults: 1 g/dose q 12 hr PO (max dose: 3 g/24 hr).
 
|
|
''Cautions: ''Rash, Stevens-Johnson syndrome, nausea, leukopenia, crystalluria. Renal and hepatic elimination; avoid use with renal disease. Half-life 12 hr. Initial dose often a loading dose (doubled).
* Photosensitivity
 
* Hypersensitivity
''Drug interactions: ''Protein displacement with warfarin, phenytoin, methotrexate.
* Hepatic impairment
 
|-
|-
| '''Tobramycin'''
|
|
'''Sulfisoxazole '''Gantrisin. Tablet: 500 mg.
* E. coli
 
* Klebsiella
Suspension: 500 mg/5 mL. Ophthalmic solution, ointment.
* Enterobacter
 
* Serratia
* Proteus
* Pseudomonas
|
|
'''Sulfonamide antibiotic used for the treatment of otitis media, chronic bronchitis, and lower urinary tract infections due to susceptible bacteria.'''
* Neonates (postnatal age ≤ 7 days): 2.5 mg/kg q12-18 hr IV or IM (&lt; 2,000 g); 2.5 mg/kg q 12 hr IV or IM (&gt; 2,000 g)
 
* Neonates (postnatal age &gt; 7 days): 2.5 mg/kg q 8-12 hr IV or IM (&lt; 2,000 g); 2.5 mg/kg q 8 hr IV or IM (&gt; 2,000 g)
Children: 120-150 mg/kg/24 hr divided q 4-6 hr PO (max dose: 6 g/24 hr).
* Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM; 5-7.5 mg/kg/24 hr IV
 
* Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM
Adults: 4-8 g/24 hr divided q 4-6 hr PO.
 
|
|
''Cautions: ''Rash, Stevens-Johnson syndrome, nausea, leukopenia, crystalluria. Renal and hepatic elimination; avoid use with renal disease. Half-life ∼7-12 hr. Initial dose often a loading dose (doubled).
* Ototoxicity
 
* Nephrotoxicity
''Drug interactions: ''Protein displacement with warfarin, phenytoin, methotrexate.
 
|-
|-
| '''Trimethoprim'''
|
|
'''Ticarcillin '''Ticar. Injection.
* E. coli
 
* Klebsiella
* P. mirabilis
* Enterobacter
* P. jirovecii
|
|
'''Extended-spectrum penicillin active against ''E. coli, Enterobacter, Serratia, P. aeruginosa, ''and ''Bacteroides.'''''
* Children (&lt; 12 yr): 4-6 mg/kg/24 hr divided q 12 hr PO
 
* Children (&gt; 12 yr) and adults: 100-200 mg q 12 hr PO
Neonates: Postnatal age ≤7 days 2,000 g: 150 mg/kg/24 hr divided  q 8-12 hr IV; 7 days 2,000 g: 225 mg/kg/24 hr divided q 8 hr IV;
 
7 days 1,200 g: 150 mg/kg/24 hr divided q 12 hr IV; 1,200-
 
2,000 g: 225 mg/kg/24 hr divided q 8 hr IV; 2,000 g: 300 mg/
 
kg/24 hr divided q 6-8 hr IV.
 
Children: 200-400 mg/kg/24 hr divided q 4-6 hr IV; cystic fibrosis: 400-600 mg/kg/24 hr IV.
 
Adults: 2-4 g/dose q 4-6 hr IV (max dose: 24 g/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia); painful given intramuscularly; each gram contains 5-6 mEq sodium. Interferes with platelet aggregation; increases in liver function tests. Renally eliminated. Inactivated by penicillinase.
* Megaloblastic anemia
 
* Bone marrow suppression
''Drug interaction: ''Probenecid.
* Nausea
 
* Epigastric distress
* Rash
|-
|-
| '''Vancomycin'''
|
|
'''Ticarcillin-clavulanate'''
* Gram-positive pathogens including Staphylococcus, S. pneumoniae, and Enterococcus
 
* C. difficile
Timentin. Injection.
 
|
|
'''Extended-spectrum penicillin (ticarcillin) combined with a'''
* Neonates (postnatal age &gt; 7 days): 15 mg/kg/24 hr divided q 24 hr IV (&lt; 1,200 g); 15 mg/kg/24 hr divided q 12-18 hr IV (1,200–2,000 g); 30 mg/kg/24 hr divided q 12 hr IV (&gt; 2,000 g)
 
* Neonates (postnatal age &gt; 7 days): 15 mg/kg/24 hr divided q 24 hr IV (&lt; 1,200 g); 15 mg/kg/24 hr divided q 8-12 hr IV (1,200–2,000 g); 45 mg/kg/24 hr divided q 8 hr IV (&gt; 2,000 g)
β-lactamase inhibitor (clavulanate) active against ''S. aureus, H. influenzae, Enterobacter, E. coli, Serratia, P. aeruginosa, Acinetobacter, ''and ''Bacteroides.'''''
* Children: 45-60 mg/kg/24 hr divided q 8-12 hr IV
 
* C. difficile–associated colitis: 40-50 mg/kg/24 hr divided q 6-8 hr PO; 40-50 mg/kg/24 hr divided q 6-8 hr PO
Children: 280-400 mg/kg/24 hr q 4-8 hr IV or IM.
 
Adults: 3.1 g q 4-8 hr IV or IM (max dose: 18-24 g/24 hr).
 
|
|
''Cautions: ''-Lactam safety profile (rash, eosinophilia); painful given intramuscularly; each gram contains 5-6 mEq sodium. Interferes with platelet aggregation; increases in liver function tests. Renally eliminated.
* Ototoxicity
 
* Nephrotoxicity
''Drug interaction: ''Probenecid.
 
|-
|
'''Tigecycline '''Tygacil. Injection.
 
|
'''Tetracycline-class antibiotic (glycylcycline) active against Enterobacteriaceae, including ESBL producers; streptococci (including VRE); staphylococci (including MRSA); and anaerobes.'''
 
Children: unknown.
 
Adults: 100 mg loading dose followed by 50 mg q 12 hr IV.
 
|
''Cautions: ''Pregnancy; children under 8 yr of age; photosensitivity; hypersensitivity to tetracyclines; hepatic impairment (~60% hepatic  clearance).
 
''Drug interaction: ''Warfarin; mycophenolate mofetil.
 
|-
|
'''Tobramycin '''Nebcin, Tobrex. Injection.
 
Ophthalmic solution, ointment.
 
|
'''Aminoglycoside antibiotic active against gram-negative bacilli, especially ''E. coli, Klebsiella, Enterobacter, Serratia, Proteus, ''and ''Pseudomonas.'''''
 
Neonates: Postnatal age ≤7 days, 1,200-2,000 g: 2.5 mg/kg q
 
12-18 hr IV or IM; 2,000 g: 2.5 mg/kg q 12 hr IV or IM; postnatal
 
age 7 days, 1,200-2,000 g: 2.5 mg/kg q 8-12 hr IV or IM;
 
2,000 g: 2.5 mg/kg q 8 hr IV or IM.
 
Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM. Alternatively
 
may administer 5-7.5 mg/kg/24 hr IV. Preservative-free preparation for intraventricular or intrathecal use: neonate: 1 mg/24 hr; children: 1-2 mg/24 hr; adults: 4-8 mg/24 hr.
 
Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM.
 
|
''Cautions: S. pneumoniae, ''other ''Streptococcus, ''and anaerobes are resistant. May cause ototoxicity and nephrotoxicity. Monitor renal function. Drug eliminated renally. Administered IV over 30-60 min.
 
''Drug interactions: ''May potentiate other ototoxic and nephrotoxic drugs.
 
''Target serum concentrations: ''Peak 6-12 mg/L; trough 2 mg/L.
 
|-
|
'''Trimethoprim '''Proloprim, Trimpex. Tablet: 100, 200 mg
 
|
'''Folic acid antagonist effective in the prophylaxis and treatment of ''E. coli, Klebsiella, P. mirabilis, ''and ''Enterobacter ''urinary tract infections; ''P. carinii ''pneumonia.'''
 
Children: For urinary tract infection: 4-6 mg/kg/24 hr divided q 12 hr PO.
 
Children ''12 yr and adults: ''100-200 mg q 12 hr PO. ''P. carinii ''pneumonia (with dapsone): 15-20 mg/kg/24 hr divided q 6 hr for 21 days PO.
 
|
''Cautions: ''Megaloblastic anemia, bone marrow suppression, nausea, epigastric distress, rash.
 
''Drug interactions: ''Possible interactions with phenytoin, cyclosporine, rifampin, warfarin.
 
|-
|
'''Vancomycin '''Vancocin,  Luphocin. Injection.
 
Capsule: 125 mg, 250 mg. Suspension.
 
|
'''Glycopeptide antibiotic active against most gram-positive pathogens including ''Staphylococcus ''(including ''MRSA ''and coagulase-negative staphylococci), ''S. pneumoniae ''including penicillin-resistant strains, ''Enterococcus ''(resistance is increasing), and ''C. difficile–as''sociated colitis.'''
 
Neonates: Postnatal age ≤7 days, 1,200 g: 15 mg/kg/24 hr divided q 24 hr IV; 1,200-2,000 g: 15 mg/kg/24 hr divided q 12-18 hr IV;
 
2,000 g: 30 mg/kg/24 hr divided q 12 hr IV; postnatal age 7
 
days, 1,200 g: 15 mg/kg/24 hr divided q 24 hr IV; 1,200-2,000 g:
 
15 mg/kg/24 hr divided q 8-12 hr IV; 2,000 g: 45 mg/kg/24 hr
 
divided q 8 hr IV.
 
Children: 45-60 mg/kg/24 hr divided q 8-12 hr IV; ''C. difficile''– associated colitis; 40-50 mg/kg/24 hr divided q 6-8 hr PO.
 
40-50 mg/kg/24 hr divided q 6-8 hr PO.
 
|
''Cautions: ''Ototoxicity and nephrotoxicity particularly when co-administered with other ototoxic and nephrotoxic drugs.
 
Infuse IV over 45-60 min. Flushing (red man syndrome) associated with rapid IV infusions, fever, chills, phlebitis (central line is preferred). Renally eliminated.
 
''Target serum concentrations: ''Peak (1 hr after
 
1 hr infusion) 30-40 mg/L; trough 5-10 mg/L.
 
|}
|}

Latest revision as of 07:03, 3 June 2015

Antibiotic Agent Antimicrobial Spectrum Dosing Information Notable Adverse Reaction
Amikacin
  • Escherichia coli
  • Klebsiella
  • Proteus
  • Enterobacter
  • Serratia
  • Pseudomonas
  • Neonates (postnatal age ≤ 7 days): 7.5 mg/kg q 12-18 hr IV or IM (≤ 2,000 g); 10 mg/kg q 12 hr IV or IM (> 2,000 g)
  • Neonates (postnatal age > 7 days): 7.5 mg/kg q 8-12 hr IV or IM (≤ 2,000 g); 10 mg/kg q 8 hr IV or IM (> 2,000 g)
  • Children: 15-25 mg/kg/24 hr divided q 8-12 hr IV or IM
  • Adults: 15 mg/kg 24 hr divided q 8-12 hr IV or IM
  • Ototoxicity
  • Nephrotoxicity
Amoxicillin
  • Gram-positive pathogens except Staphylococcus
  • Salmonella
  • Shigella
  • Neisseria
  • E. coli
  • Proteus mirabilis
  • Children: 20-50 mg/kg/24 hr divided q 8-12 hr PO. Higher dose of 80-90 mg/kg 24 hr PO for otitis media
  • Adults: 250-500 mg q 8-12 hr PO
  • Rash
  • Diarrhea
  • Cramping
Amoxicillin-Clavulanate
  • S. aureus, methicillin-susceptible
  • Streptococcus
  • Haemophilus influenzae
  • Moraxella catarrhalis
  • E. coli
  • Klebsiella
  • Bacteroides fragilis
  • Neonates: 30 mg/kg/24 hr divided q 12 hr PO.
  • Children: 20-45 mg/kg 24 hr divided q 8-12 hr PO. Higher dose 80-90 mg/kg/24 hr PO for otitis media.
  • Diarrhea
  • Rash
Ampicillin
  • Gram-positive pathogens except Staphylococcus
  • Salmonella
  • Shigella
  • Neisseria
  • E. coli
  • Proteus mirabilis
  • Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (≤ 2,000 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
  • Neonates (postnatal age > 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (< 1,200 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (1,200–2,000 g); 100 mg/kg/24 hr divided q 6 hr IV or IM (> 2,000 g)
  • Children: 100-200 mg/kg/24 hr divided q 6 hr IV or IM
  • Adults: 250-500 mg q 4-8 hr IV or IM
  • Diarrhea
Ampicillin-Sulbactam
  • S. aureus
  • H. influenzae
  • M. catarrhalis
  • E. coli
  • Klebsiella
  • B. fragilis
  • Children: 100-200 mg/kg/24 hr divided q 4-8 hr IV or IM
  • Adults: 1-2 g q 6-8 hr IV or IM (max daily dose: 8 g)
  • Diarrhea
  • Rash
Azithromycin
  • S. aureus
  • Streptococcus
  • H. influenzae
  • Mycoplasma
  • Legionella
  • Chlamydia trachomatis
  • Children: 10 mg/kg PO on day 1 (max dose: 500 mg) followed by 5 mg/kg PO q 24 hr for 4 days.
  • Adults: 500 mg PO day 1 followed by 250 mg for 4 days.
  • Gastrointestinal distress
Aztreonam
  • Gram-negative aerobic bacteria
  • Enterobacteriaceae
  • Pseudomonas aeruginosa
  • Neonates (postnatal age ≤ 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (≤ 2,000 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
  • Neonates (postnatal age > 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (< 1,200 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (1,200–2,000 g); 120 mg/kg/24 hr divided q 6-8 hr IV or IM (> 2,000 g)
  • Children: 90-120 mg/kg/24 hr divided q 6-8 hr IV or IM
  • Adults: 1-2 g IV or IM q 8-12 hr (max dose: 8 g/24 hr)
  • Rash
  • Thrombophlebitis
  • Eosinophilia
Carbenicillin
  • Enterobacter
  • Proteus
  • Pseudomonas
  • Neonates (postnatal age ≤ 7 days): 225 mg/kg/24 hr divided q 8 hr IV or IM (≤ 2,000 g); 300 mg/kg/24 hr divided q 6 hr IV or IM (> 2,000 g)
  • Neonates (postnatal age > 7 days): 300-400 mg/kg/24 hr divided q 6 hr IV or IM
  • Children: 400-600 mg/kg/24 hr divided q 4-6 hr IV or IM
  • Rash
  • Liver transaminases elevation
Cefaclor
  • S. aureus
  • S. pneumoniae
  • H. influenzae
  • E. coli
  • Klebsiella
  • Proteus
  • Children: 20-40 mg/kg/24 hr divided q 8-12 hr PO (max dose: 2 g)
  • Adults: 250-500 mg q 6-8 hr PO
  • Rash
  • Eosinophilia
  • Serum sickness-like reaction
Cefadroxil
  • S. aureus
  • Streptococcus
  • E. coli
  • Klebsiella
  • Proteus
  • Children: 30 mg/kg/24 hr divided q 12 hr PO (max dose: 2 g)
  • Adults: 250-500 mg q 8-12 hr PO
  • Rash
  • Eosinophilia
Cefazolin
  • S. aureus
  • Streptococcus
  • E. coli
  • Klebsiella
  • Proteus
  • Neonates (postnatal age ≤ 7 days): 40 mg/kg/24 hr divided q 12 hr IV or IM
  • Neonates (postnatal age > 7 days): 40-60 mg/kg/24 hr divided q 8 hr IV or IM
  • Children: 50-100 mg/kg/24 hr divided q 8 hr IV or IM
  • Adults: 0.5-2g q 8 hr IV or IM (max dose: 12 g/24 hr)
  • Rash
  • Eosinophilia
Cefdinir
  • Extended-spectrum cephalosporin
  • Children: 14 mg/kg/24 hr in 1 or 2 doses PO (max dose: 600 mg/24 hr)
  • Adults: 600 mg q 24 hr PO
  • Diarrhea
Cefepime
  • Gram-positive bacteria
  • Gram-negative bacteria including P. aeruginosa
  • Children: 100-150 mg/kg/24 hr q 8-12 hr IV or IM
  • Adults: 2-4 g/24 hr q 12 hr IV or IM
  • Diarrhea
  • Nausea
  • Vaginal candidiasis
  • Rash
  • Eosinophilia
Cefixime
  • Streptococci
  • H. influenzae
  • M. catarrhalis
  • Neisseria gonorrhoeae
  • Serratia marcescens
  • P. vulgaris
  • Children: 8 mg/kg/24 hr divided q 12-24 hr PO
  • Adults: 400 mg/24 hr divided q 12-24 hr PO
  • Rash
  • Eosinophilia
Cefoperazone
  • Gram-positive pathogens
  • Gram-negative pathogens
  • Neonates: 100 mg/kg/24 hr divided q 12 hr IV or IM
  • Children: 100-150 mg/kg/24 hr divided q 8-12 hr IV or IM
  • Adults: 2-4 g/24 hr divided q 8-12 hr IV or IM (max dose: 12 g/24 hr)
  • Hypoprothrombinemia
  • Disulfiram-life reaction
Cefotaxime
  • Gram-positive pathogens
  • Gram-negative pathogens
  • Neonates (postnatal age ≤ 7 days): 100 mg/kg/24 hr divided q 12 hr IV or IM
  • Neonates (postnatal age > 7 days): 100 mg/kg/24 hr divided q 12 hr IV or IM (< 1,200 g); 150 mg/kg/24 hr divided q 8 hr IV or IM (> 1,200 g)
  • Children: 150 mg/kg/24 hr divided q 6-8 hr IV or IM
  • Adults: 1-2 g q 8-12 hr IV or IM (max dose: 12 g/24 hr)
  • Rash
  • Eosinophilia
Cefotetan
  • S. aureus
  • Streptococcus
  • H. influenzae
  • E. coli
  • Klebsiella
  • Proteus
  • Bacteroides
  • Children: 40-80 mg/kg/24 hr divided IV or IM q 12 hr
  • Adults: 2-4 g/24 hr divided q 12 hr IV or IM (max dose: 6 g/24 hr)
  • Rash
  • Eosinophilia
  • Hypoprothrombinemia
  • Disulfiram-life reaction
Cefoxitin
  • S. aureus
  • Streptococcus
  • H. influenzae
  • E. coli
  • Klebsiella
  • Proteus
  • Bacteroides
  • Neonates: 70-100 mg/kg/24 hr divided q 8-12 hr IV or IM
  • Children: 80-160 mg/kg/24 hr divided q 6-8 hr IV or IM
  • Adults: 1-2 g q 6-8 hr IV or IM (max dose: 12 g/24 hr)
  • Rash
  • Eosinophilia
Cefpodoxime
  • S. aureus
  • Streptococcus
  • H. influenzae
  • M. catarrhalis
  • N. gonorrhoeae
  • E. coli
  • Klebsiella
  • Proteus
  • Children: 10 mg/kg/24 hr divided q 12 hr PO
  • Adults: 200-800 mg/24 hr divided q 12 hr PO (max dose: 800 mg/24 hr)
  • Rash
  • Eosinophilia
Cefprozil
  • S. aureus
  • Streptococcus
  • H. influenzae
  • E. coli
  • M. catarrhalis
  • Klebsiella
  • Proteus
  • Children: 30 mg/kg/24 hr divided q 8-12 hr PO
  • Adults: 500-1,000 mg/24 hr divided q 12 hr PO (max dose: 1.5 g/24 hr)
  • Rash
  • Eosinophilia
Ceftazidime
  • Gram-positive pathogens
  • Gram-negative pathogens including P. aeruginosa
  • Neonates (postnatal age ≤ 7 days): 100 mg/kg/24 hr divided q 12 hr IV or IM
  • Neonates (postnatal age > 7 days): 100 mg/kg/24 hr divided q 12 hr IV or IM (< 1,200 g); 150 mg/kg/24 hr divided q 8 hr IV or IM (> 1,200 g)
  • Children: 150 mg/kg/24 hr divided q 8 hr IV or IM
  • Adults: 1-2 g q 8-12 hr IV or IM (max dose: 8-12 g/24 hr)
  • Rash
  • Eosinophilia
Ceftiaoxime
  • Gram-positive pathogens
  • Gram-negative pathogens
  • Children: 150 mg/kg/24 hr divided q 6-8 hr IV or IM
  • Adults: 1-2 g q 6-8 hr IV or IM (max dose: 12 g/24 hr)
  • Rash
  • Eosinophilia
Ceftriaxone
  • Gram-positive pathogens
  • Gram-negative pathogens
  • Neonates: 50-75 mg/kg q 24 hr IV or IM
  • Children: 50-75 mg/kg q 24 hr IV or IM
  • Adults: 1-2 g q 24 hr IV or IM (max dose: 4 g/24 hr)
  • Rash
  • Eosinophilia
Cefuroxime
  • S. aureus
  • Streptococcus
  • H. influenzae
  • E. coli
  • M. catarrhalis
  • Klebsiella
  • Proteus
  • Neonates: 40-100 mg/kg/24 hr divided q 12 hr IV or IM
  • Children: 200-240 mg/kg/24 hr divided q 8 hr IV or IM; 20-30 mg/kg/24 hr divided q 8 hr PO
  • Adults: 750-1,500 mg q 8 hr IV or IM (max dose: 6 g/24 hr)
  • Rash
  • Eosinophilia
Cephalexin
  • S. aureus
  • Streptococcus
  • E. coli
  • Klebsiella
  • Proteus
  • Children: 25-100 mg/kg/24 hr divided q 6-8 hr PO
  • Adults: 250-500 mg q 6 hr PO (max dose: 4 g/24 hr)
  • Rash
  • Eosinophilia
Cephradine
  • S. aureus
  • Streptococcus
  • E. coli
  • Klebsiella
  • Proteus
  • Children: 50-100 mg/kg/24 hr divided q 6-12 hr PO
  • Adults: 250-500 mg q 6-12 hr PO (max dose: 4 g/24 hr)
  • Rash
  • Eosinophilia
Chloramphenicol
  • Gram-positive pathogens
  • Salmonella
  • Enterococcus faecium
  • Bacteroides
  • Mycoplasma
  • Chlamydia
  • Rickettsia
  • Neonates: loading dose of 20 mg/kg followed by
  • Neonates (postnatal age ≤ 7 days): 25 mg/kg/24 hr q 24 hr IV
  • Neonates (postnatal age > 7 days): 25 mg/kg/24 hr q 24 hr IV (< 2,000 g); 50 mg/kg/24 hr divided q 12 hr IV (> 2,000 g)
  • Children: 50-75 mg/kg/24 hr divided q 6-8 hr IV or PO
  • Adults: 50 mg/kg/24 hr divided q 6 hr IV or PO (max dose: 4 g/24 hr)
  • Gray-baby syndrome
  • Bone marrow suppression
  • Aplastic anemia
Ciprofloxacin
  • P. aeruginosa
  • Serratia
  • Enterobacter
  • Shigella
  • Salmonella
  • Campylobacter
  • N. gonorrhoeae
  • H. influenzae
  • M. catarrhalis
  • Neonates: 10 mg/kg q 12 hr PO or IV
  • Children: 15-30 mg/kg/24 hr divided q 12 hr PO or IV
  • Adults: 250-750 mg q 12 hr; 200-400 mg IV q 12 hr PO (max dose: 1.5 g/24 hr)
  • Tendonitis
  • Dizziness
  • Confusion
  • Crystalluria
  • Photosensitivity
Clarithromycin
  • S. aureus
  • Streptococcus
  • H. influenzae
  • Legionella
  • Mycoplasma
  • C. trachomatis
  • Children: 15 mg/kg/24 hr divided q 12 hr PO
  • Adults: 250-500 mg q 12 hr PO (max dose: 1 g/24 hr)
  • Gastrointestinal distress
  • Dyspepsia
  • Nausea
  • Cramping
Clindamycin
  • Gram-positive aerobic pathogens
  • Anaerobic cocci except Enterococcus
  • Neonates (postnatal age ≤ 7 days): 10 mg/kg/24 hr divided q 12 hr IV or IM (≤ 2,000 g); 15 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
  • Neonates (postnatal age > 7 days): 10 mg/kg/24 hr IV or IM divided q 12 hr (≤ 1,200 g); 15 mg/kg/24 hr divided q 8 hr IV or IM (1,200–2,000 g); 20 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
  • Children: 10-40 mg/kg/24 hr divided q 6-8 hr IV, IM, or PO
  • Adults: 150-600 mg q 6-8 hr IV, IM, or PO (max dose: 5 g/24 hr IV or IM or 2 g/24 hr PO)
  • Diarrhea
  • Nausea
  • Pseudomembranous colitis
  • Rash
Cloxacillin
  • S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci
  • Children: 50-100 mg/kg/24 hr divided q 6 hr PO
  • Adults: 250-500 mg q 6 hr PO (max dose: 4 g/24 hr)
  • Rash
  • Eosinophilia
Trimethoprim-Sulfamethoxazole
  • Shigella
  • Legionella
  • Nocardia
  • Chlamydia
  • Pneumocystis jirovecii
  • Children: 6-20 mg TMP/kg/24 hr or IV divided q 12 hr PO
  • Adults: 160 mg TMP q 12 hr PO
  • Rash
  • Erythema multiforme
  • Stevens-Johnson syndrome
  • Nausea
  • Leukopenia
Demeclocycline
  • Gram-positive cocci except Enterococcus
  • Gram-negative bacilli
  • Anaerobes
  • Borrelia burgdorferi
  • Mycoplasma
  • Chlamydia
  • Children: 8-12 mg/kg/24 hr divided q 6-12 hr PO
  • Adults: 150 mg PO q 6-8 hr
  • Teeth staining
  • Photosensitivity
  • Diabetes insipidus
  • Nausea
  • Vomiting
  • Diarrhea
Dicloxacillin
  • S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci
  • Children: 12.5-100 mg/kg/24 hr divided q 6 hr PO
  • Adults: 125-500 mg q 6 hr PO
  • Rash
  • Eosinophilia
Doripenem
  • Gram-positive cocci
  • Gram-negative bacilli including P. aeruginosa
  • Anaerobes
  • Adults: 500 mg q 8 hr IV
  • Rash
  • Eosinophilia
Doxycycline
  • Gram-positive cocci except Enterococcus
  • Gram-negative bacilli
  • Anaerobes
  • B. burgdorferi
  • Mycoplasma
  • Chlamydia
  • Children: 2-5 mg/kg/24 hr divided q 12-24 hr PO or IV (max dose: 200 mg/24 hr)
  • Adults: 100-200 mg/24 hr divided q 12-24 hr PO or IV
  • Teeth staining
  • Photosensitivity
  • Nausea
  • Vomiting
  • Diarrhea
Erythromycin
  • Gram-positive organisms
  • Corynebacterium diphtheriae
  • Mycoplasma pneumoniae
  • Neonates (postnatal age ≤ 7 days): 20 mg/kg/24 hr divided q 12 hr PO
  • Neonates (postnatal age > 7 days): 20 mg/kg/24 hr divided q 12 hr PO (< 1,200 g); 30 mg/kg/24 hr divided q 8 hr PO (> 1,200 g)
  • Children: Usual max dose 2 g/24 hr. Base: 30-50 mg/kg/24 hr divided q 6-8 hr PO. Estolate: 30-50 mg/kg/24 hr divided q 8-12 hr PO. Stearate: 20-40 mg/kg/24 hr divided q 6 hr PO. Lactobionate: 20-40 mg/kg/24 hr divided q 6-8 hr IV. Gluceptate: 20-50 mg/kg/24 hr divided q 6 hr IV; usual max dose 4 g/24 hr IV
  • Adults: Base: 333 mg PO q 8 hr; estolate/stearate/base: 250-500 mg q 6 hr PO
  • Cramping
  • Nausea
  • Vomiting
  • Diarrhea
  • Hypertrophic pyloric stenosis
Gentamicin
  • E. coli
  • Klebsiella
  • Proteus
  • Enterobacter
  • Serratia
  • Pseudomonas
  • Neonates (postnatal age ≤ 7 days): 2.5 mg/kg q 12-18 hr IV or IM (< 2,000 g); 2.5 mg/kg q 12 hr IV or IM (> 2,000 g)
  • Neonates (postnatal age > 7 days): 2.5 mg/kg q 8-12 hr IV or IM (< 2,000 g); 32.5 mg/kg q 8 hr IV or IM (> 2,000 g)
  • Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM; 5-7.5 mg/kg/24 hr IV once daily
  • Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM
  • Ototoxicity
  • Nephrotoxicity
Imipenem-Cilastatin
  • Gram-positive cocci
  • Gram-negative bacilli including P. aeruginosa
  • Anaerobes
  • Neonates (postnatal age ≤ 7 days): 20 mg/kg q 18-24 hr IV or IM (< 1,200 g); 40 mg/kg divided q 12 hr IV or IM (> 1,200 g)
  • Neonates (postnatal age > 7 days): 40 mg/kg q 12 hr IV or IM (< 2,000 g); 60 mg/kg q 8 hr IV or IM (> 2,000 g)
  • Children: 60-100 mg/kg/24 hr divided q 6-8 hr IV or IM
  • Adults: 2-4 g/24 hr divided q 6-8 hr IV or IM (max dose: 4 g/24 hr)
  • Rash
  • Eosinophilia
  • Nausea
  • Seizures
Linezolid
  • Staphylococcus
  • Streptococcus
  • E. faecium
  • Enterococcus faecalis
  • Children: 10 mg/kg q 12 hr IV or PO
  • Adults: Pneumonia: 600 mg q 12 hr IV or PO
  • Bone marrow suppression
  • Pseudomembranous colitis
  • Nausea
  • Diarrhea
  • Headache
Loracarbef
  • S. aureus
  • Streptococcus
  • H. influenzae
  • M. catarrhalis
  • E. coli
  • Klebsiella
  • Proteus
  • Children: 30 mg/kg/24 hr divided q 12 hr PO (max dose: 2 g)
  • Adults: 200-400 mg q 12 hr PO (max dose: 800 mg/24 hr)
  • Rash
  • Eosinophilia
Meropenem
  • Gram-positive cocci
  • Gram-negative bacilli including P. aeruginosa
  • Anaerobes
  • Children: 60 mg/kg/24 hr divided q 8 hr IV
  • Adults: 1.5-3 g q 8 hr IV
  • Rash
  • Eosinophilia
Metronidazole
  • Anaerobes
  • Neonates (postnatal age ≤ 7 days): 7.5 mg/kg 48 hr PO or IV (< 1,200 g); 7.5 mg/kg/24 hr q 24 hr PO or IV (1,200–2,000 g); 15 mg/kg/24 hr divided q 12 hr PO or IV (> 2,000 g)
  • Neonates (postnatal age > 7 days): 5 mg/kg/24 hr divided q 12 hr PO or IV (< 2,000 g); 30 mg/kg/24 hr divided q 12 hr PO or IV (> 2,000 g)
  • Children: 30 mg/kg/24 hr divided q 6-8 hr PO or IV
  • Adults: 30 mg/kg/24 hr divided q 6 hr PO or IV (max dose: 4 g/24 hr)
  • Dizziness
  • Seizures
  • Metallic taste
  • Nausea
  • Hypoprothrombinemia
  • Disulfiram-like reaction
Mezlocillin
  • E. coli
  • Enterobacter
  • Serratia
  • Bacteroides
  • Neonates (postnatal age ≤ 7 days): 150 mg/kg/24 hr divided q 12 hr IV
  • Neonates (postnatal age > 7 days): 225 mg/kg divided q 8 hr IV
  • Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV
  • Adults: 2-4 g/dose q 4-6 hr IV (max dose: 12 g/24 hr)
  • Rash
  • Eosinophilia
  • Liver transaminases elevation
Mupirocin
  • Staphylococcus
  • Streptococcus
  • Topical application to the skin 2-4 times per day
  • Itching
Nafcillin
  • S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci
  • Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr divided q 12 hr IV or IM (< 2,000 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
  • Neonates (postnatal age > 7 days): 75 mg/kg/q 8 hr IV (< 2,000 g); 100 mg/kg divided q 6-8 hr IV (> 2,000 g)
  • Children: 100-200 mg/kg/24 hr divided q 4-6 hr IV
  • Adults: 4-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr)
  • Rash
  • Eosinophilia
  • Phlebitis
  • Neutropenia
Nalidixic acid
  • E. coli
  • Enterobacter
  • Klebsiella
  • Proteus
  • Children: 50-55 mg/kg/24 hr divided q 6 hr PO; suppressive therapy 25-33 mg/kg/24 hr divided q 6-8 hr PO
  • Adults: 1 g q 6 hr PO; suppressive therapy: 500 mg q 6 hr PO
  • Vertigo
  • Dizziness
  • Rash
Neomycin
  • Gastrointestinal flora
  • Infants: 50 mg/kg/24 hr divided q 6 hr PO
  • Children: 50-100 mg/kg/24 hr divided q 6-8 hr PO
  • Adults: 500-2,000 mg/dose q 6-8 hr PO
  • Cramping
  • Diarrhea
  • Rash
  • Ototoxicity
  • Nephrotoxicity
Nitrofurantoin
  • Gram-positive pathogens
  • Gram-negative pathogens
  • Children: 5-7 mg/kg/24 hr divided q 6 hr PO (max dose: 400 mg/24 hr); suppressive therapy 1-2.5 mg/kg/24 hr divided q 12-24 hr PO (max dose: 100 mg/24 hr)
  • Adults: 50-100 mg/24 hr divided q 6 hr PO
  • Vertigo
  • Dizziness
  • Rash
  • Jaundice
  • Interstitial pneumonitis
Ofloxacin
  • Gram-positive pathogens
  • Gram-negative pathogens
  • Anaerobes
  • Chlamydia trachomatis
  • Child (< 12 yr): Conjunctivitis: 1-2 drops in affected eye(s) q 2-4 hr for 2 days, then 1-2 drops qid for 5 days. Corneal ulcers: 1-2 drops q 30 min while awake and at 4 hours at night for 2 days, then 1-2 drops hourly for 5 days while awake, then 1-2 drops q 6 hr for 2 days. Otitis externa: 5 drops into affected ear bid for 10 days
  • Child (> 12 yr) and adults: Ophthalmic solution doses same as for younger children. Otitis externa: 10 drops bid for 10–14 days as for younger children
  • Burning
  • Stinging
  • Eye redness
  • Dizziness
Oxacillin
  • S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci
  • Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr divided q 12 hr IV (< 2,000 g); 75 mg/kg/24 hr IV divided q 8 hr IV (> 2,000 g)
  • Neonates (postnatal age > 7 days): 50 mg/kg/24 hr IV divided q 12 hr IV (< 1,200 g); 75 mg/kg/24 hr divided q 8 hr IV (1,200–2,000 g); 100 mg/kg/24 hr IV divided q 6 hr IV (> 2,000 g)
  • Infants: 100-200 mg/kg/24 hr divided q 4-6 hr IV
  • Children: PO 50-100 mg/kg/24 hr divided q 4-6 hr IV
  • Adults: 2-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr)
  • Rash
  • Eosinophilia
  • Neutropenia
Penicillin G
  • S. pneumoniae
  • Group A Streptococcus
  • N. gonorrhoeae
  • N. meningitidis
  • Neonates (postnatal age ≤ 7 days): 50,000 units/kg/24 hr divided q 12 hr IV or IM (< 2,000 g); 75,000 units/kg/24 hr divided q 8 hr IV or IM (> 2,000 g)
  • Neonates (postnatal age > 7 days): 50,000 units/kg/24 hr divided q 12 hr IV (< 1,200 g); 75,000 units/kg/24 hr q 8 hr IV (1,200–2,000 g); 100,000 units/kg/24 hr divided q 6 hr IV (> 2,000 g)
  • Children: 100,000-250,000 units/kg/24 hr divided q 4-6 hr IV or IM (max dose: 400,000 units/kg/24 hr)
  • Adults: 2-24 million units/24 hr divided q 4-6 hr IV or IM
  • Rash
  • Eosinophilia
  • Allergy
  • Seizures
Penicillin G, benzathine
  • Group A Streptococcus
  • Neonates: 50,000 units/kg IM once
  • Children: 300,000-1.2 million units/kg q 3-4 wk IM (max dose: 1.2-2.4 million units/dose)
  • Adults: 1.2 million units IM q 3-4 wk
  • Rash
  • Eosinophilia
  • Allergy
Penicillin G, procaine
  • Gram-positive pathogens
  • Neonates: 50,000 units/kg/24 hr IM
  • Children: 25,000-50,000 units/kg/24 hr IM for 10 days (max dose: 4.8 million units/dose)
  • Adults: 0.6-4.8 million units q 12-24 hr IM
  • Rash
  • Eosinophilia
  • Allergy
Penicillin V
  • S. pneumoniae
  • N. gonorrhoeae
  • N. meningitidis
  • Children: 25-50 mg/kg/24 hr divided q 4-8 hr PO
  • Adults: 125-500 mg q 6-8 hr PO (max dose: 3 g/24 hr)
  • Rash
  • Eosinophilia
  • Allergy
Piperacillin
  • E. coli
  • Enterobacter
  • Serratia
  • P. aeruginosa
  • Bacteroides
  • Neonates (postnatal age ≤ 7 days): 150 mg/kg/24 hr divided q 8-12 hr IV
  • Neonates (postnatal age > 7 days): 200 mg/kg divided q 6-8 hr IV
  • Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV
  • Adults: 2-4 g/dose q 4-6 hr (max dose: 24 g/24 hr) IV
  • Rash
  • Eosinophilia
  • Serum sickness-like reaction
Piperacillin-Tazobactam
  • S. aureus
  • H. influenzae
  • E. coli
  • Enterobacter
  • Serratia
  • Acinetobacter
  • P. aeruginosa
  • Bacteroides
  • Children: 300-400 mg/kg/24 hr divided q 6-8 hr IV or IM
  • Adults: 3.375 g q 6-8 hr IV or IM
  • Rash
  • Eosinophilia
Quinupristin-Dalfopristin
  • E. faecium, vancomycin-resistant
  • S. aureus, methicillin-resistant
  • Children and adults: 7.5 mg/kg q 8 hr IV
  • Pain
  • Edema
  • Phlebitis
  • Nausea
  • Diarrhea
Sulfadiazine
  • E. coli
  • P. mirabilis
  • Klebsiella
  • Neonates: 100 mg/kg/24 hr divided q 12 hr PO with pyrimethamine 1 mg/kg/24 hr PO with folinic acid
  • Children: 120-200 mg/kg/24 hr divided q 6 hr PO with pyrimethamine 2 mg/kg/24 hr divided q 12 hr PO ≥3 days then 1 mg/kg/24 hr (max dose: 25 mg/24 hr) with folinic acid
  • Rash
  • Stevens-Johnson syndrome
  • Nausea
  • Leukopenia
  • Crystalluria
Sulfamethoxazole
  • Bacteria associated with otitis media, chronic bronchitis, and lower urinary tract infections
  • Children: 50-60 mg/kg/24 hr divided q 12 hr PO
  • Adults: 1 g/dose q 12 hr PO (max dose: 3 g/24 hr)
  • Rash
  • Stevens-Johnson syndrome
  • Nausea
  • Leukopenia
  • Crystalluria
Sulfisoxazole
  • Bacteria associated with otitis media, chronic bronchitis, and lower urinary tract infections
  • Children: 120-150 mg/kg/24 hr divided q 4-6 hr PO (max dose: 6 g/24 hr)
  • Adults: 4-8 g/24 hr divided q 4-6 hr PO
  • Rash
  • Stevens-Johnson syndrome
  • Nausea
  • Leukopenia
  • Crystalluria
Ticarcillin
  • E. coli
  • Enterobacter
  • Serratia
  • P. aeruginosa
  • Bacteroides
  • Neonates (postnatal age ≤ 7 days): 150 mg/kg/24 hr divided q 8-12 hr IV
  • Neonates (postnatal age > 7 days): 150 mg/kg/24 hr divided q 8-12 hr IV (< 1,200 g); 150 mg/kg/24 hr divided q 12 hr IV (1,200–2,000 g); 300 mg/kg/24 hr divided q 6-8 hr IV (> 2,000 g)
  • Children: 200-400 mg/kg/24 hr divided q 4-6 hr IV
  • Adults: 2-4 g/dose q 4-6 hr IV (max dose: 24 g/24 hr)
  • Rash
  • Eosinophilia
  • Liver transaminases elevation
Ticarcillin-Clavulanate
  • S. aureus
  • H. influenzae
  • Enterobacter
  • E. coli
  • Serratia
  • P. aeruginosa
  • Acinetobacter
  • Bacteroides
  • Children: 280-400 mg/kg/24 hr q 4-8 hr IV or IM
  • Adults: 3.1 g q 4-8 hr IV or IM (max dose: 18-24 g/24 hr)
  • Rash
  • Eosinophilia
  • Liver transaminases elevation
Tigecycline
  • Enterobacteriaceae including ESBL producers
  • Streptococcus
  • Staphylococcus
  • Anaerobes
  • Adults: 100 mg loading dose followed by 50 mg q 12 hr IV
  • Photosensitivity
  • Hypersensitivity
  • Hepatic impairment
Tobramycin
  • E. coli
  • Klebsiella
  • Enterobacter
  • Serratia
  • Proteus
  • Pseudomonas
  • Neonates (postnatal age ≤ 7 days): 2.5 mg/kg q12-18 hr IV or IM (< 2,000 g); 2.5 mg/kg q 12 hr IV or IM (> 2,000 g)
  • Neonates (postnatal age > 7 days): 2.5 mg/kg q 8-12 hr IV or IM (< 2,000 g); 2.5 mg/kg q 8 hr IV or IM (> 2,000 g)
  • Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM; 5-7.5 mg/kg/24 hr IV
  • Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM
  • Ototoxicity
  • Nephrotoxicity
Trimethoprim
  • E. coli
  • Klebsiella
  • P. mirabilis
  • Enterobacter
  • P. jirovecii
  • Children (< 12 yr): 4-6 mg/kg/24 hr divided q 12 hr PO
  • Children (> 12 yr) and adults: 100-200 mg q 12 hr PO
  • Megaloblastic anemia
  • Bone marrow suppression
  • Nausea
  • Epigastric distress
  • Rash
Vancomycin
  • Gram-positive pathogens including Staphylococcus, S. pneumoniae, and Enterococcus
  • C. difficile
  • Neonates (postnatal age > 7 days): 15 mg/kg/24 hr divided q 24 hr IV (< 1,200 g); 15 mg/kg/24 hr divided q 12-18 hr IV (1,200–2,000 g); 30 mg/kg/24 hr divided q 12 hr IV (> 2,000 g)
  • Neonates (postnatal age > 7 days): 15 mg/kg/24 hr divided q 24 hr IV (< 1,200 g); 15 mg/kg/24 hr divided q 8-12 hr IV (1,200–2,000 g); 45 mg/kg/24 hr divided q 8 hr IV (> 2,000 g)
  • Children: 45-60 mg/kg/24 hr divided q 8-12 hr IV
  • C. difficile–associated colitis: 40-50 mg/kg/24 hr divided q 6-8 hr PO; 40-50 mg/kg/24 hr divided q 6-8 hr PO
  • Ototoxicity
  • Nephrotoxicity
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_g15&oldid=1104941"